
Amended Safety Assessment of Amorphous Silica and Synthetically-Manufactured Amorphous Silicates as Used in Cosmetics

Status: Tentative Amended Report for Public Comment
Release Date: June 19, 2019
Panel Meeting Date: September 16-17, 2019

All interested persons are provided 60 days from the above release date (i.e. August 18, 2019) to comment on this safety assessment and to identify additional published data that should be included or provide unpublished data which can be made public and included. Information may be submitted without identifying the source or the trade name of the cosmetic product containing the ingredient. All unpublished data submitted to CIR will be discussed in open meetings, will be available at the CIR office for review by any interested party and may be cited in a peer-reviewed scientific journal. Please submit data, comments, or requests to the CIR Executive Director, Dr. Bart Heldreth.

The 2019 Cosmetic Ingredient Review Expert Panel members are: Chair, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Ronald A. Hill, Ph.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; James G. Marks, Jr., M.D.; Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Executive Director is Bart Heldreth, Ph.D. This safety assessment was prepared by Christina L. Burnett, Senior Scientific Analyst/Writer.

ABSTRACT

The Cosmetic Ingredient Review (CIR) Expert Panel (Panel) assessed the safety of amorphous Silica and 23 synthetically-manufactured silicate ingredients; 16 of these ingredients were previously reviewed by the Panel, and 8 are reviewed herein for the first time. The Panel considered the method of manufacture of these ingredients to be of significant importance when reviewing safety. Thus, the current assessment is exclusive to amorphous ingredients when manufactured via synthetic methods. Most of these ingredients are reported to function as abrasives, absorbents, bulking agents, and/or deodorant agents in cosmetic products. The Panel reviewed relevant new data, including frequency and concentration of use, and considered the data from previous CIR reports. The Panel concluded that amorphous Silica and Hydrated Silica are safe in the present practices of use and concentration when formulated to be non-irritating. The data on the remaining 22 silicate ingredients are insufficient to issue a determination of safety.

INTRODUCTION

The Panel previously reviewed the safety of Aluminum Silicate, Calcium Silicate, Magnesium Silicate, Magnesium Trisilicate, Sodium Magnesium Silicate, Zirconium Silicate, Lithium Magnesium Silicate, and Lithium Magnesium Sodium Silicate in a report that was published in 2003.¹ The Panel concluded that these ingredients are safe as used in cosmetic products. In accordance with its procedures, the Panel evaluates the conclusions of previously-issued reports every 15 years, and it has been at least 15 years since this assessment has been issued. This report has been reopened to add additional ingredients, including several that were also previously reviewed. Potassium Silicate, Sodium Metasilicate, and Sodium Silicate (report published in 2005) were found to be safe for use in cosmetic products in the practices of use and concentration described in the safety assessment when formulated to avoid irritation,² and Silica, Aluminum Iron Silicates, Hydrated Silica, Magnesium Aluminometasilicate (previously known as Alumina Magnesium Metasilicate), and Sodium Potassium Aluminum Silicate (report finalized in 2009) were determined to be safe as cosmetic ingredients in the practices of use and concentrations as described in the safety assessment.³

In total, this report assesses the safety of 24 ingredients (listed below; previously reviewed ingredients are in red) as used in cosmetics. According to the web-based *International Cosmetic Ingredient Dictionary and Handbook* (wINCI; *Dictionary*; see Table 1), the majority of these ingredients are reported to function as abrasives, absorbents, bulking agents, and/or deodorant agents in cosmetic products.⁴

Aluminum Iron Calcium Magnesium Germanium Silicates

Aluminum Iron Calcium Magnesium Zirconium Silicates

Aluminum Iron Silicates

Aluminum Silicate

Ammonium Silver Zinc Aluminum Silicate

Calcium Magnesium Silicate

Calcium Silicate

Hydrated Silica

Lithium Magnesium Silicate

Lithium Magnesium Sodium Silicate

Magnesium Aluminometasilicate

Magnesium Silicate

Magnesium Trisilicate

Potassium Silicate

Silica

Sodium Magnesium Aluminum Silicate

Sodium Magnesium Silicate

Sodium Metasilicate

Sodium Potassium Aluminum Silicate

Sodium Silicate

Sodium Silver Aluminum Silicate

Tromethamine Magnesium Aluminum Silicate

Zinc Silicate

Zirconium Silicate

The Panel considered the method of manufacture of these ingredients (whether synthetic or mined) to be of significant importance when reviewing safety. Thus, the current assessment is exclusive to the above amorphous ingredients when manufactured via synthetic methods.

The Panel has also reviewed other related ingredients. The Panel determined that silylates and surface-modified siloxysilicates (i.e., silica silylate, silica dimethyl silylate, trimethylsiloxysilicate, and trifluoropropyldimethyl/trimethylsiloxysilicate) are safe as used in cosmetics when formulated and delivered in the final product not to be irritating or sensitizing to the respiratory tract.⁵ The ingredients included in these reports are not part of this amended safety assessment.

This safety assessment includes relevant published and unpublished data that are available for each endpoint that is evaluated. Published data are identified by conducting an exhaustive search of the world's literature. A listing of the search engines and websites that are used and the sources that are typically explored, as well as the endpoints that CIR typically evaluates, is provided on the CIR website (<https://www.cir-safety.org/supplementaldoc/preliminary-search-engines-and-websites>; <https://www.cir-safety.org/supplementaldoc/cir-report-format-outline>). Unpublished data are provided by the cosmetics industry, as well as by other interested parties.

Some chemical and toxicological data on the Silica and synthetically-manufactured silicate ingredients included in this safety assessment were obtained from robust summaries of data submitted to the European Chemical Agency (ECHA) by companies as part of the REACH chemical registration process.⁶⁻¹² Additionally, some data were obtained from assessments by the Organisation for Economic Co-Operation and Development Screening Information Data Sets (OECD SIDS)^{13,14} and the European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC).¹⁵ These data summaries are available on the

ECHA, OECD SIDS, and ECETOC websites, respectively, and when deemed appropriate, information from the summaries has been included in this report.

Excerpts from the summaries of the 2003 and 2005 reports are disseminated throughout the text of this re-review document, as appropriate, and are identified by *italicized text*. (This information, except for chemical and physical properties, is not included in the tables or the summary section.) The Silica report (finalized in 2009) has been incorporated into this safety assessment due to reorganization. The original reports that were published or finalized in 2003, 2005, and 2009, and the report on related ingredients, are available on the CIR website (<https://www.cir-safety.org/ingredients>).

CHEMISTRY

Definition

These inorganic oxide ingredients, comprising in part, silicon dioxide, are solids that can be derived from naturally occurring minerals. However, the ingredients in this safety assessment can be produced synthetically, and in the case of Silica and Hydrated Silica, these are more commonly prepared as such for commercial purposes. The Panel considered the method of manufacture of these ingredients (whether synthetic or mined) to be of significant importance to safety. Thus, the current assessment is exclusive to the ingredients herein when manufactured via synthetic methods. The definitions and functions of the Silica and synthetically-manufactured silicate ingredients included in this safety assessment are provided in Table 1.

Silica

Silica is a silicon-oxygen tetrahedral unit, in which a silicon atom is central within 4 oxygen atoms that are shared with adjacent silicon atoms.¹⁶ Various physical forms of Silica are caused by differences in the spatial relationships of the tetrahedral that determine physical characteristics. Amorphous Silica has an irregular tetrahedral pattern. Crystalline Silica is polymorphic, where each variety has a characteristic regular 3-dimensional arrangement of the tetrahedral. As would be predicted from these descriptions, crystalline Silica has a well-defined x-ray diffraction pattern, whereas amorphous forms of Silica do not. (Only amorphous Silica is included in this safety assessment.)

The CAS No. 7631-86-9 is a general CAS No. which includes all forms of silicas, including amorphous, crystalline, synthetic, and natural forms.¹⁴ The amorphous forms of Silica may also be referred to as amorphous silicon oxide hydrate, silicic anhydride, silicon dioxide, and silicon dioxide, fumed.⁴ Pyrogenic Silica is the current terminology for silicon dioxide, fumed.³ The CAS No. 112945-52-5 has been reported to be associated with synthetic pyrogenic Silica, whereas the CAS Nos. 67762-90-7; 68611-44-9; and 68909-20-6 have been reported to be associated with synthetic surface treated Silica.¹⁷

Hydrated Silica

Hydrated Silica may also be referred to as hydrosilicic acid, precipitated silica, silica gel, silica hydrate, silicic acid, silicic acid hydrate, silicon dioxide hydrate, synthetic amorphous silicon dioxide, and colloidal silica.^{4,18} The CAS No. 112926-00-8 has been reported to be associated with both synthetic precipitated silica and silica gel.¹⁷

Physical and Chemical Properties

Physical and chemical properties of amorphous Silica and the synthetically-manufactured silicate ingredients are provided in Table 2. Most of these ingredients generally are not soluble in water, but a few, like Calcium Silicate and Silica, have limited water solubility.

Silica and Hydrated Silica

According to size distribution measurements taken by several manufacturers of various synthetic amorphous silica and silicate raw materials, the median particle sizes of these ingredients are approximately between 6 - 682 μm .¹⁹ Particle size was reported to range from as small as $< 1 \mu\text{m}$ to as large as 2060 μm ; data submitted to CIR reported that for 11 out of 20 samples, 0.15% to 80.1% of the particle measured 10 μm or less. However, these measurements will change once these ingredients are formulated in cosmetic products due to aggregation of the particles. These manufacturers also reported the size distribution of various synthetic amorphous silica and silicate ingredients are approximately between 8 – 65 μm , with particle size ranges of approximately $< 1 - 344 \mu\text{m}$.

The *Food Chemicals Codex* states that Silica is a white, fluffy non-gritty powder of extremely fine particle size that is hygroscopic.²⁰ Silica absorbs moisture from the air in varying amounts. Amorphous silicas are composed of very fine particles (average of 20 μm) which tend to aggregate loosely in the air.²¹ Primary particles, or single particles, exist only in the colloidal form of Hydrated Silica.^{15,22} Aggregates assemble in chains (Silica; pyrogenic) or clusters (Hydrated Silica; precipitated and gel). Agglomerates are assemblies of aggregates, held together by strong physical adhesion forces and not in a dispersible nano-size ($< 100 \text{ nm}$).

The acidity of synthetic amorphous Silica is related to the number and reactivity of the silanol groups present on the solid Silica surface.²³ Surface silanols ($\text{pK}_a = 7.1$) are more acidic than monosilicic acid ($\text{pK}_a = 9.8$). The acidity increases with the degree of polymerization. The surface of Silica may be made up of free silanol groups (isolated hydroxyls), hydrogen-bonded silanol groups (hydroxyl groups on adjacent surface silicon atoms), and siloxane groups. Amorphous Silica is capable

of rehydroxylating in aqueous systems to form a high ratio of silanol to siloxane groups. Depending on the hydrophobic properties of the solvent, it may form a network-like structure through hydrogen bonding. This gives amorphous Silica gelling and thickening abilities in various solvent systems. Oxygen electron donors of compounds such as ethers, alcohols, and ketones or the nitrogen of amides and amines may interact through hydrogen bonding due to the acid dissociation constant of the silanol groups on the Silica surface. Esterification has been reported with a Si-O-C-R structure. A totally dehydrated Silica or a fully hydrated Silica has little or no adsorption of hydrophobic organocompounds.

Method of Manufacturing

Aluminum Silicate is a naturally occurring mineral as well as artificially produced.¹ Synthetic Aluminum Silicate is formed by heating compositions of controlled proportions of Silica, alumina, and alkalis under conditions to promote the specific structure. Sodium Silicate and Sodium Metasilicate are either made by high temperature fusion of Silica and soda or by a hydrothermal process using Silica and sodium hydroxide as starting materials.² Potassium Silicate can be also be produced by high temperature fusion of potassium carbonate and sand.

Silica and Hydrated Silica

Amorphous Silica and Hydrated Silica used in cosmetics are produced synthetically.^{14,15,17} A manufacturing process for Silica (pyrogenic form) is shown in Figure 1. Mean particle size, particle size distribution, and degree of aggregation and/or agglomeration can be determined by adjusting processing parameters.²⁴

Silica may be produced by a vapor-phase process.²⁵ The pyrogenic form of Silica is produced in a relatively anhydrous state. Hydrated Silica is produced by a wet process and contains a large amount of bound water.

Composition/Impurities

Silica

Silica has been reported to be > 95% to > 99.6% pure.^{14,19} Possible impurities include: sodium oxide (0.2% to 2.1% wt.), sulfur trioxide (0.2% to 3.0% wt.), iron (III) oxide (< 0.05% wt.), and other trace oxides (< 0.07% wt.). Heavy metal limits include: antimony (< 5 ppm), barium (< 50 ppm), chromium (< 10 ppm), arsenic (< 3 ppm), lead (< 10 ppm), mercury (< 1 ppm), cadmium (< 1 ppm), and selenium (< 1 ppm).

Sodium Metasilicate

The arsenic and lead maximum limits in Sodium Metasilicate are 3 ppm and 20 ppm, respectively.²

Sodium Silicate

The arsenic and lead maximum limits in Sodium Silicate (40% solution) are 3 ppm and 20 ppm, respectively.²

USE

Cosmetic

The safety of the cosmetic ingredients included in this assessment is evaluated based on data received from the US Food and Drug Administration (FDA) and the cosmetics industry on the expected use of these ingredients in cosmetics. Use frequencies of individual ingredients in cosmetics are collected from manufacturers and reported by cosmetic product category in the FDA Voluntary Cosmetic Registration Program (VCRP) database. Use concentration data are submitted by the cosmetics industry in response to surveys, conducted by the Personal Care Products Council (Council), of maximum reported use concentrations by product category.

According to 2019 VCRP data, Silica has the most reported uses in cosmetic products, with a total of 8222; the majority of the uses are in leave-on makeup preparations (e.g., eye makeup, lipsticks, foundations, and face powders; Table 3 and Table 4).²⁷ Hydrated Silica had the second most reported uses in cosmetic products, with a total of 462; the majority of the uses are in rinse-off oral hygiene and personal cleanliness products. The frequencies of use for Silica and Hydrated Silica have greatly increased since the original safety assessments were finalized; in 2009, Silica was reported to have 3276 uses and Hydrated Silica was reported to have 176 uses.³ According to 2019 VCRP data, the reported numbers of uses for the remaining ingredients in this report are much lower than what is reported for Silica and Hydrated Silica.

The results of the concentration of use surveys conducted in 2018 by the Council indicate Silica has the highest reported maximum concentration of use; it is used at up to 82% in face and neck products and 50% in mascaras and lipsticks.^{28,29} Hydrated Silica is used at up to 33.8% in oral hygiene products and at up to 10% in leave-on skin care products. According to the original safety assessment, in 2008, the maximum use concentration reported for Silica was 44% in eye shadows,³ and the maximum use concentration reported for Hydrated Silica was 34% in dentifrices, with a maximum leave-on concentration of 4% in face powders. Cosmetic ingredients with no reported uses in the VCRP database or in the Council's concentration of use survey are listed in Table 5.

Many of the Silicate ingredients described in this safety assessment may be used in products that can be incidentally ingested or come into contact with mucous membranes; for example, Silica is reported to be used in lipsticks at up to 50%, and

Hydrated Silica is reported to be in dentifrices at up to 17.1%.²⁹ Additionally, these ingredients have been reported to be used in products that may come into contact with the eyes, such as eye shadows, eye liners, and mascaras. Silica is reported to be used at up to 50% in mascaras,²⁹ and Magnesium Silicate at up to 20% in eyeliners.²⁸ Moreover, these ingredients are reported to be used in spray products that could possibly be inhaled; for example, Silica is reported to be used at up to 2% in aerosol hair spray and at up to 0.84% in aerosol deodorants.²⁹ Concerning final consumer product formulations (typically a mixture of ingredients), the Panel has noted that in practice, 95% to 99% of the droplets/particles released from cosmetic sprays have aerodynamic equivalent diameters > 10 µm, with propellant sprays yielding a greater fraction of droplets/particles below 10 µm compared with pump spray.³⁰⁻³³ Therefore, most droplets/particles incidentally inhaled from cosmetic sprays would be deposited in the nasopharyngeal and bronchial regions and would not be respirable (i.e., they would not enter the lungs) to any appreciable amount.^{30,32} There is some evidence indicating that deodorant spray products can release substantially larger fractions of particulates having aerodynamic equivalent diameters in the range considered to be respirable.³² However, the information is not sufficient to determine whether significantly greater lung exposures result from the use of deodorant sprays, compared to other cosmetic sprays. Ingredients in this report are also used in powders, and these products could possibly be inhaled. For example, Silica is reported to be used at up to 66% in face powders.²⁹ Conservative estimates of inhalation exposures to respirable particles during the use of loose powder cosmetic products are 400-fold to 1000-fold less than protective regulatory and guidance limits for inert airborne respirable particles in the workplace.³⁴⁻³⁶

In regulations on cosmetic products in the European Union, zirconium and its compounds (including Zirconium Silicate) are listed under Annex II-substances prohibited in cosmetic products.³⁷ Aluminum Silicate is listed under Annex IV – colorants allowed in cosmetic products. The remaining Silicate-related ingredients listed in this report are not restricted from use in any way under the rules governing cosmetic products in the European Union.

Non-Cosmetic

Aluminum Silicate is approved as an indirect food additive, according to the Code of Federal Regulations (CFR).¹ Calcium Silicate and Magnesium Trisilicate are used in over-the-counter drug products.

Potassium Silicate and Sodium Silicate were reported as being used in industrial cleaners and detergents.² Sodium Metasilicate is a generally recognized as safe (GRAS) food ingredient.

According to Australia's National Industrial Chemicals Notification and Assessment Scheme (NICNAS), the following ingredients are Tier I chemicals (not considered to pose an unreasonable risk to the health of workers and public health): Aluminum Silicate, Calcium Silicate, Magnesium Silicate, Magnesium Trisilicate, Sodium Potassium Aluminum Silicate, and Silica (as amorphous, fumed, crystalline-free; gel; gel-precipitated, crystalline-free; and vitreous).³⁸ Potassium Silicate, Sodium Silicate, and Sodium Metasilicate are Tier II chemicals (require risk management measures to be instituted for safe use for human health or the environment). The remaining silicates have no NICNAS determination.

Calcium Silicate

Calcium Silicate is used in endodontics in root canal sealer preparations and dental cements.³⁹⁻⁴¹

Hydrated Silica

Hydrated Silica (colloidal) is used in fiber, sizing, diazo paper manufacture, cellophane film, ceramics, glass fiber, paints, batteries, foods, and polishing.⁴²

Silica

Silica is used in pharmaceuticals as a thickener in pastes and ointments to inhibit the separation of components and maintain flow properties in powder products.¹⁴ It is also a general excipient for pharmaceuticals.^{43,44} Silica can function as a carrier for fragrances.¹⁴ Silica is used in animal feed as carriers and anticaking agents in vitamins and mineral premixes. Silica is also used in paints, lacquers, plastics, paper, and in the production of “green tires”. Silica is used as an insecticide by cuticular lipid layer dehydration. Silica is used as reinforcing fillers for many non-staining and colored rubber and silicone products.^{14,21}

Silica has many uses in foods and food preparations.^{14,20,44} These include use as an anticaking agent in dry powders, a dispersion agent for dry powders in liquids, an anti-settling or suspending agent, a stabilizer in oil/water emulsions, a thickening or thixotropic agent, a gelling agent, a flavor carrier, an extrusion aid, a clarification and separation aid, and a support matrix for immobilization of enzymes. It is also used as a defoaming agent, conditioning agent, a chill-proofing agent in malt beverages, and a filter aid in foods.

Sodium Magnesium Aluminum Silicate

Sodium Magnesium Aluminum Silicate is reported to be used in print enhancement (imparting high brightness and opacity), paper filler, and carbonless copy intensifier.⁴⁵

Zinc Silicate

Zinc Silicate is reported to be used as phosphors (in television screens), in spray ingredients (spray type not stated), and to remove traces of copper from gasoline.^{45,46}

TOXICOKINETICS

Absorption, Distribution, Metabolism, Excretion (ADME)

No statistically significant absorption of aluminum was recorded in assayed plasma samples of dogs given Magnesium Trisilicate orally.¹ This study did note elevated levels of silicon. The urinary excretion of Silica was 5.2% in human males given 20 g of Magnesium Trisilicate.

Sodium Silicate administered orally in rats acts as a mild alkali and was readily absorbed from the alimentary canal and excreted in the urine.² Urinary excretion of Sodium Silicate given orally to rats at 40 and 1000 mg/kg was 18.9% and 2.8%, respectively.

Animal

Oral

Silica

In an oral study of Silica (average particle size 15 μm) in an aqueous suspension, female rats (strain and number not specified) received 1500 mg/kg/d for 30 days via gavage.¹⁴ Controls were not described. The rats were then killed and necropsied. The Silica content in the livers, kidneys, and spleen was 1.5 μg (control value = 1.8 μg), 6.4 μg (7.2 μg), and 5.3 μg (7.8 μg), respectively.

In a similar study, 20 female Sprague-Dawley rats received Silica (average particle size not reported) via gavage in an aqueous suspension (100 mg/rat; ~500 mg/kg) 20 times over one month.¹⁴ Controls were not described. No clinical signs of toxicity were observed. The Silica content in the liver, spleen, and kidneys was 4.2 μg (control value = 1.8 μg), 5.5 μg (7.2 μg), and 14.2 μg (7.8 μg), respectively.

Silica, Hydrated Silica, and Sodium Metasilicate

In a dietary ADME study, 5 guinea pigs received Silica (0.8 mg/g feed) as three separate forms (Sodium Metasilicate, Hydrated Silica, and Silica solution (30%)) in single doses or in four repeated doses every 48 h.^{47,48} Urine and feces were collected in 48-h increments after each dose of each form and analyzed for Silica content. For the Sodium Metasilicate doses, the urinary output of Silica peaked within 48 h and gradually returned to normal after 8 days. When administered four times, 48 h apart, the peak was maintained, but did not increase. Within 48 h after the last dose, the concentration of Silica in the urine began to return to normal. With the Silica solution and Hydrated Silica, the urinary output of Silica also peaked within 48 h and gradually returned to normal after 8 days, but the peaks were much lower than those observed with Sodium Metasilicate. When administered four times, 48 h apart, the Silica concentrations behaved similarly to the Sodium Metasilicate form, except with a lower peak. In this study, approximately 63% of the Silica was recovered. The authors of the study suggested that the Silica in the urine was in the soluble or molybdate reactive form, and that the Silica particles underwent depolymerization prior to excretion.

Inhalation

Silica

The retention and elimination of aerosolized Silica (initial dose and particle size not reported) was studied in female inbred albino rats (strain and number not reported).¹⁴ The rats were exposed to the test material 4 h/day, 5 days/week, for 40 days. The amount was then increased to 40 to 50 mg/m³ until day 120. Groups of rats were killed and necropsied periodically through the test period.

The average 1-day retention value was 28 $\mu\text{g/lung}$ at the lower unspecified concentration. During the first 10 days, a steep linear increase was seen with ~28 $\mu\text{g/day}$, as theoretically expected. Increments then became smaller. The author suggested that elimination increased and that an equilibrium between retention and elimination was established. After 40 exposures, the average 1-day retention value was 59 $\mu\text{g/lung}$ at the high concentration. After 120 exposures, the total deposit (lung and mediastinal lymph nodes) was 435 $\mu\text{g/lung}$, equivalent to 7.4% of the theoretically deposited material (5840 $\mu\text{g/lung}$, based on the measured 1-day retention); more than 92% of the deposited Silica in the alveoli was eliminated during the exposure period. At that time, the mean retention in the lungs was 300 $\mu\text{g/lung}$ (~ 69% of the total). The deposition rate in the mediastinal lymph nodes was negligible during the first 40 days, but increased gradually. After 120 exposures, the retention was substantial amounting to 135 μg (~ 31% of the total deposit). A test for the determination of free alveolar cells showed a decrease immediately after a single exposure and 24 h later an increase of 100% was observed.¹⁴

In another retention and elimination study, female Sprague-Dawley rats (number not reported) were exposed to aerosolized Silica (0.050 to 0.055 mg/l; particle size not provided) for 5 h/day for 5 days/week for one year.¹⁴ Because the rats

had occurrences of bronchitis, putrid lung inflammation, and pronounced cell reactions, the exposure incidences were reduced to 2 or 3 days/week. Rats in each group were killed and necropsied periodically during treatment and after treatment.

After 6 weeks of treatment, Silica was observed in the lungs (0.5 mg) and the mediastinal lymph node (0.02 mg); after 18 weeks these values were 1.2 mg and 0.11 mg, respectively, and after 12 months, the values were 1.37 mg and 0.13 mg, respectively. Corresponding to the respiration volume, 1% of the inhaled Silica was retained in the lungs. After a recovery period of 5 months, there was 0.160 mg and 0.047 mg Silica observed in the lungs and mediastinal lymph node, respectively, with a reduction of 88% in the lung and > 50% in the lymph nodes. The increase in lung deposition was rapid at the initial exposure; amounts of deposited Silica were low from 18 weeks to 12 months of exposure.¹⁴

Groups of 10 male and 10 female Wistar rats were exposed to Silica (0, 0.51, 2.05, or 10.01 mg/m³; particle size not provided) for 6 h/day, 5 days/week, for 13 weeks.¹⁵ A group of rats from each dose group was allowed to recover for 13 weeks before being killed and necropsied. Silica was observed in the lungs in a concentration dependent manner at the end of exposure. Silica was observed in the tracheobronchial lymph nodes in the high dose group. After recovery, the amount of Silica in the lungs was below detection limits in the low dose group and only a small amount was detected in the high dose group.

Rats (strain and number not provided) were exposed to aerosolized Silica (hydrophilic; 50 to 55 mg/m³) for 12 months.¹⁵ Rats were killed and necropsied periodically and after 5 months recovery. There was 0.25 mg Silica in the lung at day 3, and 0.5 mg at 6 weeks. At 12 months, ~1% of the total administered respirable Silica was observed in the lungs. Initial accumulation was rapid and dropped off between week 18 and 12 months (0.5 mg at 6 weeks; 1.2 mg at 18 weeks; 1.37 mg at 12 months). The mediastinal lymph nodes contained ~0.02 mg Silica at 6 weeks and 0.13 at 12 months. After 5 months of recovery, the Silica in the lungs decreased to 0.16 mg/lung (88% reduction) and 0.047 mg/lymph node (> 50% reduction).

Rats (strain and number not provided) were exposed to aerosolized Silica (hydrophobic; 50 mg/m³; particle size not provided) for 5 h/day, 2 days/week, for 8 and 12 months.¹⁵ After 8 months, the lungs retained 1.448 mg Silica (1.3% of exposure) and after 12 months, 1.759 mg Silica (1.1%). The lymph nodes retained 0.05 and 0.113 mg, respectively. After a 12-month exposure and 1-month recovery, the lungs contained 1.1 mg Silica (37.5% elimination) and the lymph nodes contained 0.16 mg. After 3 months recovery, the lungs contained 0.43 mg and the lymph nodes 0.12 mg Silica. After 5 months recovery, the lungs contained 0.41 mg (76.7% elimination) and the lymph nodes 0.13 mg Silica.

Rats (strain and number not provided) were exposed to aerosolized Silica (hydrophobic; 100 mg/m³; particle size not provided) for up to 1 year.¹⁵ Silica content of the lungs and the lymph nodes was 4.33 and 0.132 mg at 3 months, 6.71 and 0.214 mg at 5 months, and 11.46 and 0.378 mg at 12 months, respectively. After 6 months of recovery, 55.5% of the Silica was eliminated from the lungs. Lymph node elimination could not be observed.

In an elimination study, aerosolized Silica (0.05 mg/l; particle size not provided) was administered for 5 h/day for 3 days to female Sprague-Dawley rats (number not specified).¹⁴ The rats were observed for up to 3 months. Twenty hours after the last exposure, 0.25 mg Silica were found in the lungs. After 3 months, the Silica content was 0.018 mg. In the lymph node, 0.018 mg Silica was found after 1 month and 0.008 mg Silica after 3 months.

An elimination study was performed on rats (details not provided) exposed to aerosolized Silica (hydrophobic; 50 mg/m³; particle size not provided) for 1 or 3 days.¹⁵ The rats were killed and necropsied after 20 h, 1 month, or 3 months. At 1-month recovery, elimination of Silica was 78% (1 day exposure) and 75% (3 days exposure). After 3 months recovery, elimination was 87% and 92%, respectively. There was little Silica in the mediastinal lymph nodes.

Rats (details not provided) were exposed to aerosolized Silica (hydrophobic; 200 mg/m³; particle size not provided) in an elimination study for 5 h/d for 3 days.¹⁵ After a 3-month recovery period, 81% of the Silica was eliminated. Elimination by the lymph nodes was marginal.

Hydrated Silica

In an elimination study of Hydrated Silica (55 mg/m³; average particle size 15 µm), rats (details not provided) were exposed to the test material for 5 h.¹⁴ The mean retention value at 20 h was 0.138 mg/lung. The mean Silica-content of the lungs for Hydrated Silica was 1.022 mg after 4 months recovery and 3.113 mg after 12 months recovery. The corresponding values for the mediastinal lymphatic nodes were 0.033 mg and 0.069 mg, respectively. Five months after exposure, the average value for the lungs was only 0.457 mg (87% elimination rate) and 0.052 mg for the mediastinal lymphatic nodes.

Subcutaneous

Silica

In a subcutaneous study in female Sprague-Dawley rats (number not provided), 6.89 mg Silica was measured in the tissue 24 h after a single dose of 10 mg was injected.¹⁴ One month after injection, the amount of Silica had decreased to 0.646 mg, and after 2 months, the amount of Silica at the injection site was 0.298 mg.

In another study, Silica (10 mg in water) was subcutaneously injected in rats (no further details).¹⁵ The Silica was quickly removed from the injection site with a mean recovery of 6.90 mg at 24 h, 0.65 mg after 1 month, and 0.30 mg after 2 months.

Approximately 95% to 97% of Silica (30, 40, or 50 mg in water) injected subcutaneously in rats was recovered 6 weeks after treatment (no further details).¹⁵

Human

Oral

Silica and Hydrated Silica

Excretion of orally administered Silica and Hydrated Silica (as 1250 mg of Silica in apple juice) was evaluated in 2 groups of 6 volunteers (5 males and 1 female in each group).¹⁴ The solutions were consumed in 2 doses, morning and midday, on the same day. The total urine was collected daily and analyzed. During the 4 days post-treatment, changes of renal Silica secretion were not observed. Daily Silica increments in urine after ingestion ranged between 7 and 23 mg. For Silica, the individual baseline values of the pre-test phase were very variable and individually different; mean excretion rates ranged from 25 to 87 mg/day. In the post-treatment phase, individual mean excretion rates ranged from 32 to 61 mg/day. For Hydrated Silica, the individual baseline values of the pre-test phase were very variable and individually different; mean excretion rates ranged from 16 to 71 mg/day. In the post-treatment phase, individual mean excretion rates ranged from 20 to 81 mg/day. Overall, increases in excretion were not unequivocally detectable. The authors noted that the small apparent increases were in marked contrast to the high dose of 2500 mg Silica ingested.

TOXICOLOGICAL STUDIES

Acute Toxicity Studies

The following are acute oral LD₅₀ determinations: Calcium Silicate, 3400 mg/kg in rats; and Zirconium Silicate, > 200 g/kg in mice.¹

The toxicity of Potassium Silicate, Sodium Metasilicate, and Sodium Silicate has been related to the molar ratio of SiO₂/Na₂O and the concentration.² The acute oral LD₅₀ of Sodium Metasilicate ranged from 847 mg/kg in male rats to 1349.3 mg/kg in female rats, and from 770 mg/kg in female mice to 820 mg/kg in male mice. Gross lesions of variable severity were found in the oral cavity, pharynx, esophagus, stomach, larynx, lungs, and kidneys of dogs receiving 0.25 g/kg or more of a commercial detergent containing Sodium Metasilicate. Similar lesions were seen in pigs given the same detergent and dose as in the previous study. Male Sprague-Dawley rats orally administered 464 mg/kg of a 20% solution containing either 2.0 or 2.4 ratio of Sodium Silicate to 1.0 ratio of sodium oxide showed no signs of toxicity, whereas doses of 1000 and 2150 mg/kg produced gasping, dyspnea, and acute depression. Acute intraperitoneal injections of a neutralized 2% solution of Sodium Metasilicate in white rats resulted in a decrease in spleen weight and relative enlargement of the kidneys.

Acute dermal, oral, and inhalation data are summarized in Table 6. Hydrated Silica in water had a dermal LD₅₀ greater than 5 g/kg in rabbits; Potassium Silicate (30% solution in water) had a dermal LD₅₀ greater than 5 g/kg in rats.^{8,14,15,49} In oral rat studies, the LD₅₀s were > 2 g/kg for Aluminum Silicate (concentration not reported), Silica (in polyethylene glycol 400), Sodium Magnesium Aluminum Silicate (concentration not reported), and Sodium Silicate. Calcium Silicate (20%) and Potassium Silicate (concentration not reported) had LD₅₀s of > 10g/kg and > 5 g/kg in rats, respectively.^{7,8,10-15,25,50,51} For Hydrated Silica at 12.1% in saline, 26% in water, and undiluted, oral LD₅₀s in rats were > 5 g/kg, 40 g/kg, and > 5 g/kg, respectively.^{14,15} An oral LD₅₀ for Sodium Silicate in mice was 6.60 g/kg.¹⁰ In inhalation studies that ranged in duration from 1 to 6 hours, the LC₅₀s for Hydrated Silica (30% SiO₂), Potassium Silicate (30%), and Silica (concentration not reported) in rats were > 560 mg/m³, > 2060 mg/m³, and > 139 mg/m³, respectively.^{8,14,15,25,52}

Short-Term, Subchronic, and Chronic Toxicity Studies

In short-term oral toxicity studies, beagle dogs and rats fed Aluminum Silicate had no renal lesions.¹ Dogs and rats fed Magnesium Trisilicate for 4 weeks had polydipsia and polyuria, and all dogs had renal cortical lesions. Guinea pigs had renal lesions after 4 months of drinking Magnesium Trisilicate in their tap water.

Beagle dogs fed 2.4 g/kg/day of Sodium Silicate for 4 weeks had gross renal lesions but no impairment of renal function. In an oral subchronic study (drinking water containing 600 and 1200 ppm of added Silica), there were body weight gains in male rats, but decreases in female rats. No apparent effect of the treatment in the drinking water was found on the longevity in rats having started treatment after weaning.¹

Animal

Short-term, subchronic, and chronic toxicity studies for Hydrated Silica and Silica are summarized in Table 7.

No adverse effects were reported in a 3-week dermal study of Silica (up to 10 g/kg/day) in rabbits.^{14,15} In short-term oral studies, the no-observed-adverse-effect-level (NOAEL) for Hydrated Silica was \geq 24.2 g/kg/day in a 14-day dietary study in rats.^{14,15} The no-observed-effect-level (NOEL) was 500 mg/kg/d in a 5- to 8-week dietary study in rats that were fed up to 16,000 mg/kg/day Silica.^{25,51,53} In subchronic oral studies, the NOEL was 4000 mg/kg/day in a 13-week dietary study in rats fed Hydrated Silica at up to 4000 mg/kg/day.¹⁵ No clinical signs of toxicity or gross or microscopic changes were reported in a 13-week dietary study in rats that received up to 3500 mg/kg/day Silica.^{14,15} In oral chronic studies, lower liver weights in female rats, without significant findings at histopathological examinations, were observed in a 103-week dietary study of up to

5% Hydrated Silica in rats. No remarkable findings were observed by the same researchers of the same material in a 93-week dietary study in mice.⁵⁴ The NOAEL in a 6-month dietary rat study of up to 10% Hydrated Silica was 8980 mg/kg/day.^{14,15} No remarkable findings were reported in 6-month dietary studies of up to 10% Silica in rats, although there were increased numbers of leukocytes and eosinophils in female and male rats, respectively, and reduced liver and prostate weights in another 6-month study at up to 3 g Silica/week.⁵¹

In short-term inhalation studies with Hydrated Silica, inflammatory and pulmonary lesions were observed in rats at 30 mg/m³.^{18,55-59} Inflammatory responses were also observed in rats exposed to Silica in studies that lasted between 5 to 14 days.^{18,56,60} No significant lung histopathological findings or adverse changes in inflammatory markers were observed in rats that were exposed to nanoparticle Silica (particle size 50-79 nm; concentrations 0.4-5.4 mg/m³) for 4 weeks.⁶¹ In subchronic inhalation studies, inflammatory responses were noted in the lungs and lymph nodes along with pulmonary lesions after exposure to Hydrated Silica at 35 mg/m³ (particle and agglomerate/aggregate size 1 to ~120 µm).⁶⁰ In a 13-week inhalation study of Silica in rats, the NOEL was 1.3 mg/m³.⁶⁰ Inflammation and pulmonary lesions, including fibrosis, were noted in this study and another 13-week rat study.^{60,62} The lowest-observed-adverse-effect-concentration (LOAEC) in rabbits exposed for 9 months to Hydrated Silica was 28 mg/m³.⁶³ In inhalation studies of 9- to 12-month duration, Hydrated Silica caused pulmonary inflammation and emphysema in rats exposed to 25 to 85 mg/m³.⁶⁴ No silicotic processes were noted in studies of rabbits, rats, and guinea pigs exposed to an average of 126 mg/m³ Hydrated Silica for 12, 15, and 24 months, respectively; neoplasia was not observed.⁶⁵ In a 12-month study with Hydrated Silica and Silica in rats, the LOAEC was 6 to 9 mg/m³ due to interstitial fibrosis.⁶⁶ The same test materials also were associated with nodular fibrosis in an 18-month study with monkeys. The LOAEC in a 6-month rat inhalation study with Silica was 53 mg/m³.⁶⁴ Emphysema and fibrosis were noted around 4 months of exposure. Inflammatory responses and pulmonary lesions were noted in rat, guinea pigs, rabbits, and monkeys in studies up to 24 months in duration.^{15,67-69}

DEVELOPMENTAL AND REPRODUCTIVE TOXICITY (DART) STUDIES

Calcium Silicate (250 to 1600 mg/kg on gestation days 6 through 18) had no discernible effect on nidation or on maternal or fetal survival in rabbits.¹

Rats given Sodium Silicate (600 and 1200 ppm of added Silica) in the drinking water in reproductive studies had a reduced number of offspring; 67% of controls at 600 ppm and to 80% of controls at 1200 ppm.² Three adult rats injected intratesticularly and subcutaneously with 0.8 mM/kg of Sodium Silicate showed no morphological changes in the testes and no effect on the residual spermatozoa in the ductus deferens.

Silica

No adverse reproductive effects were reported in a dietary study of Silica (500 mg/day) in rats.^{14,15} Male and female rats (n = 40) were fed the test material for 6 months. After 4.5 months, 5 females were mated to the males that were also fed the test material. Litter size, birth weights, morphology, and development of offspring were similar to controls.

In another study, pregnant female mice were fed up to 1340 mg/kg Silica for 10 days (specific gestation days not provided).^{14,15} There were no effects on nidation or on maternal or fetal survival. Fetal abnormalities were similar to controls. The same results were reported for rats fed up to 1350 mg/kg for 10 days, hamsters fed up to 1600 mg/kg for 5 days, and rabbits fed up to 1600 mg/kg for 13 days.

In a subchronic dietary study that also investigated reproductive effects, Silica (500 mg/kg/day) was administered to female Wistar rats (number not reported) for 6 months.²⁵ The female rats were mated with male rats twice: at weeks 8 and 17. The male rats were also consuming 500 mg/kg/day. The rats were weighed periodically, blood sampled monthly (except during pregnancy), and observed daily. The progeny from both matings were examined for abnormalities. At 6 months, the rats were killed and necropsied, except for 5 rats which had a 3-week treatment-free period prior to being killed and necropsied.

Reproductive performance was similar between groups. Pathological examination revealed no differences between the groups. At the first mating, 6 control and 9 treatment dams became pregnant; 7 from each group became pregnant at the second mating. There were no treatment-related effects in litter size, birth weight, physical parameters, or behavior. Development of progeny during lactation was without adverse effects; weight gains were normal. No treatment related effects were found during gross pathology. The authors conclude that the oral NOEL was > 500 mg/kg for developmental and reproductive toxicity.²⁵

GENOTOXICITY STUDIES

No increase in mutation frequencies were seen in the Salmonella TA-1530 or G-46 assay and no significant increase in recombinant activity in the Saccharomyces D3 assay treated with Calcium Silicate.¹ A subacute dose of 150 mg/kg of Calcium Silicate in rats produced 3% breaks in bone marrow cells arrested in c-metaphase. In a metaphase spread of rat bone marrow cells, Calcium Silicate produced no significant increase in the number of aberrations compared to controls, and in a rat dominant lethal assay did not induce any dominant lethal mutations. Routes of administration were not reported for these rat studies.

*Sodium Metasilicate was nonmutagenic in a DNA damage and repair assay without metabolic activation using B. subtilis.*² *Sodium Silicate was nonmutagenic in studies using Escherichia coli strains B/Sd-4/1,3,4,5 and B/Sd-4/3,4.*

Genotoxicity data are summarized in Table 8. Aluminum Silicate, Hydrated Silica, Silica, Sodium Metasilicate, Sodium Silicate, and Zinc Silicate were not genotoxic in Ames tests, hypoxanthine-guanine phosphoribosyl transferase (HGPRT) gene mutation assays, or chromosome aberration tests.^{6,9-11,14,15,25,70-73} Chromosome aberration, dominant lethal mutation, gene mutation, and mitotic recombination studies of Hydrated Silica at up to 5000 mg/kg in mice and rats were negative.¹⁵

CARCINOGENICITY STUDIES

Silica

The International Agency for Research on Cancer (IARC) concluded that amorphous Silica is not classifiable as to its carcinogenicity to humans based on inadequate evidence in humans and inadequate evidence of increased tumors in animals.⁷⁴

Oral

Hydrated Silica

In a carcinogenicity study, groups of 10 male and 10 female B₆C₃F₁ mice received Hydrated Silica (0%, 1.25%, 2.5%, or 5%) in their feed for 93 weeks.⁵⁴ In the female mice, the frequencies of adenocarcinoma in the lungs were 1/16 (6.25%) for the control group and 1/19 (5.3%), 0/20 (0%), and 1/20 (5%) for the low, mid and high dose groups. In the males, the frequencies of adenocarcinoma in the lungs were 1/16 (6.25%) for the control and 2/17 (11.8%), 3/14 (21.4%), and 3/16 (18.8%) for the low, mid, and high dose groups. There was low correlation of hyperplastic nodules/hepatocellular carcinoma/hemangioma/fibrosarcoma in the treatment groups compared to the controls. The researchers concluded that the non-neoplastic lesions were of no toxicological significance.

Silica

In a 2-year dietary study, Wistar rats (n = 40; 20 males and 20 females) received 100 mg/kg Silica (pyrogenic) in their feed.²⁵ The rats were weighed before and after treatment. At the end of the treatment period, the rats were killed and necropsied. There were no clinical signs of toxicity observed during the treatment period. The rates of tumors observed in the treated rats were comparable to historical controls. The researchers concluded that there were no carcinogenic effects from the daily ingestion of Silica in this study.

Inhalation

Hydrated Silica

The potential carcinogenic effects of aerosolized Hydrated Silica (≤ 5 μ g particle size) was studied in tumor-susceptible mice (n = 75) starting at 3 months of age.⁷⁵ The mice received 0.5 g/day Hydrated Silica in a 600 L capacity respiratory chamber once/h, 6 h/day for 5 days/week for a year. The mice were allowed to live out their natural life span for up to 917 days from the start of the experiment. The incidence of primary lung tumors was 7.9% in the control group and 21.3% in the treated group in mice that lived 10 months or longer. There was no obvious fibrosis in the lung tissue; however, there were fibrotic nodules in the trachea-bronchial lymph nodes in > 50% of the mice. The researchers suggested that most of the Silica dust was removed by cilia action through the trachea and also through the lymphatic system. Half of the treated mice had overgrowth of the mediastinal connective tissue covering the trachea-bronchial nodes which occurred in only 10% of the controls. In the treated group, 29.5% had an increase in incidence of overgrowth or hyperplasia of the trachea-bronchial lymph nodes compared to 14.3% of the controls.

Intratracheal

Silica

The carcinogenic potential of Silica (3 mg in 0.9% phosphate-buffered saline; 0.01 to 0.03 μ m) was studied in 40 female SPF Wistar rats.⁷⁶ The rats received the test material intratracheally 5 times weekly and were observed until death or month 30, at which time they were killed and necropsied. A second group of 40 rats had Silica instilled at the same dose 10 times weekly. Controls (n = 48) were untreated. The survival rates were 37/40 for group 1, 35/40 for group 2, and 46/48 for the controls. The period of time after the first treatment in which 50% of the rats died was 113 and 112 weeks in the first and second groups, respectively, and 113 weeks in the control group. The percentage of rats with macroscopic lung tumors was 13.5% in the first group, 2.9% in the second group, and 6.5% in the control group. The percentage of rats with macroscopic lung tumors which are probably not a metastasis of other tumors located elsewhere was 8.1% in the first group, none in the second group, and none in the control group. The percentage of rats with benign lung tumors in the second group was 5.7% and there were none in the control group; this was not analyzed in the first experiment. Neither the second group nor the control group had malignant tumors. The percentage of rats with lung tumors that were metastases of other primary site tumors was 14.3% in the treatment groups and 13.0% in the control group.

OTHER RELEVANT STUDIES

Cytotoxicity

A sample of Aluminum Silicate in an in vitro assay was toxic to pulmonary alveolar macrophages and lactate dehydrogenase activity (LDH) and β -galactosidase (β -GAL) release were increased.¹ Aluminum Silicate had relatively no effect on the hemolysis of rat red blood cells (RBCs). Synthetic Calcium Silicate samples and higher concentrations of Calcium Silicate caused increased hemolysis of human RBCs; a greater fibrous character of Calcium Silicate samples caused increased LDH and β -GAL release.

Immune Response

Human

Hydrated Silica

Hydrated Silica (1 to 4 mg in saline; ~15 μ m particle size) was injected subcutaneously 2 to 8 times in 28 volunteers.⁷⁷ Biopsies were taken from day 1 to 6 months. Granulomatous inflammation was observed within 7 days and persisted for months. The researchers suggested that this was a particular type of foreign body response to a fibrogenic agent and not typical epithelioid cell nodules.

DERMAL IRRITATION AND SENSITIZATION STUDIES

Sodium Magnesium Silicate (4%) had no primary skin irritation in rabbits and had no cumulative skin irritation in guinea pigs.¹ Dermal irritation of Potassium Silicate, Sodium Metasilicate, and Sodium Silicate ranged from negligible to severe, depending on the species tested and the molar ratio and concentration tested.² Sodium Metasilicate was negative in the local lymph node assay (LLNA) at up to 6%, but a delayed-type hypersensitivity response was observed to the test material in mice sensitized at 4% and challenged at 6%.

Sodium Metasilicate/carbonate detergent (37% Sodium Metasilicate) mixed 50/50 with water was considered a severe skin irritant when tested on intact and abraded human skin.² Detergents containing 7%, 13%, and 6% Sodium Silicate mixed 50/50 with water, however, were negligible skin irritants to intact and abraded human skin. Sodium Silicate (10% of a 40% aqueous solution) was negative in a human repeat-insult predictive patch test (HRIPT). The same aqueous solution of Sodium Silicate was considered mild under normal use conditions in a study of cumulative irritant properties. Sodium Metasilicate and Sodium Silicate were studied in modified soap chamber tests. No burning or itching was observed and low erythema + edema scores were noted. Sodium Metasilicate and Sodium Silicate, tested in elbow crease studies and semiocluded patch tests, produced low grade and transient irritation.

Dermal irritation and sensitization data summarized below are detailed in Table 9. Aluminum Silicate and Zinc Silicate were predicted to be not irritating in EpiDerm™ skin assays.^{6,11} In rabbit studies, the irritation potential of Potassium Silicate (up to 36%) and Sodium Metasilicate (up to 97%) were dependent on concentration.^{8,9,13} Very slight to no irritation was observed in dermal irritation studies in rabbits with Hydrated Silica (at up to 50% solution in olive oil) and Silica (up to 12% solution in methyl ethyl cellulose).^{14,15} Aluminum Silicate (up to 25%) and Zinc Silicate (up to 50%) were not sensitizing in LLNA studies.^{6,11} Potassium Silicate (30%) and Hydrated Silica (20%) was not sensitizing in guinea pig sensitization tests.^{8,78} Hydrated Silica (up to 45%) and Silica (21.74% in formulation) were not sensitizing in HRIPTs.^{14,51,79,80}

OCULAR IRRITATION STUDIES

A 4% solution of Sodium Magnesium Silicate caused minimal eye irritation in a Draize eye irritation test.¹

Potassium Silicate was nonirritating in two acute eye irritation studies in rabbits.² Sodium Metasilicate (42.4% water) was corrosive to the rabbit eye. Sodium Silicate was a severe eye irritant in acute eye irritation studies. A skin freshener (10% of a 40% aqueous solution) containing Sodium Silicate was nonirritating. Sodium Silicate in another three Draize eye irritation studies was highly irritating, irritating, and nonirritating, respectively.

In vitro and animal ocular irritation data are summarized in Table 10. Aluminum Silicate (tested pure) was predicted to be not irritating using the hen's egg test chorioallantoic membrane (HET-CAM) method.¹¹ Sodium Metasilicate (concentration not reported) was predicted to be corrosive in an in vitro method using rabbit eyes, and Zinc Silicate (20%) was predicted to be irritating in a bovine corneal opacity and permeability (BCOP) test.^{6,9} Potassium Silicate was not irritating to slightly irritating when tested at up to 35% in rabbit eyes.^{8,13} Hydrated Silica (concentration not provided) and Silica were both not irritating to slightly irritating in rabbit eyes.^{15,25,50,51}

CLINICAL STUDIES

Case Reports

Colloidal Sodium Metasilicate (0.5 l) was fatal to one man and neutralized Sodium Silicate (more than 1 g/kg) produced vomiting, diarrhea, and gastrointestinal bleeding in another man in separate case reports of oral ingestion.²

Sodium Metasilicate

Acute kidney injury was reported in a 52-year-old man who had ingested approximately 150 ml of a plate developer solution containing Sodium Metasilicate.⁸¹ The patient also developed severe upper airway obstruction due to laryngeal edema, severe inflammation of the upper gastrointestinal tract with narrowing of the esophagus and pyloric region. The patient succumbed to his injuries a few months after ingestion.

Reactive airway dysfunction syndrome was reported in a 43-year-old man who had inhaled dishwasher detergent powder containing Sodium Metasilicate.⁸² The patient was employed as an apprentice cook and accidentally inhaled the detergent while preparing to use an institutional dishwasher.

Occupational Exposure

Hydrated Silica

In an occupational study, 78 workers (aged 21 to 67 years; average 34.23 years) were examined who had been exposed to precipitated Silica from 1941 to 1959.⁸³ Dust concentrations ranged from 0.35 to 204 mg/m³. There was no evidence of silicosis or other pulmonary disease.

Workers (n = 165) exposed to Hydrated Silica for a mean of 8.6 years were examined for adverse effects.⁸⁴ Dust levels varied from < 1 to 10 mg/m³, with some higher intermittent levels. Examination included spirometers, respiratory questionnaires, and chest radiographs. Cough and dyspnea correlated with level/time of smoking and not Silica exposure. There were no correlations between yearly change of pulmonary function and dose or time of exposure. The workers with the mean exposure time of 18 years had pulmonary function similar to the rest of the group. There was radiographic evidence of minimal pneumoconiosis that was biased due to prior exposure to limestone. None of the 143 workers with exposure only to Silica showed radiographic evidence of pneumoconiosis.

Another study examined 41 workers exposed to Hydrated Silica and compared them to a control group.⁸⁵ The examination included blood gas analysis and chest radiographs. There was a reduction in forced expiratory flow in the exposed group. There was no correlation between the exposure index and pulmonary function. The authors concluded that smoking and exposure to Silica synergize to induce small airway disease.

In another unpublished occupational study of workers in Hydrated Silica factories (1952 to 1981), there was no silicosis in workers employed for 1 to > 20 years (mean 13.2 years).¹⁴ There were negative results in hematology, urine analysis, lung functions, and chest x-rays.

In an unpublished study of workers (n = 78), studied between 1941 and 1959, from a factory that manufactured Hydrated Silica pigment, dust concentrations ranged from 0.35 to 205 mg/m³.¹⁴ No evidence of silicosis or other pulmonary disease was observed. The incidence of illness and injuries were similar to other workers in this plant.

In an unpublished study, 150 workers in a Hydrated Silica factory were examined by pulmonary function test and x-ray.¹⁵ The workers were exposed for ≥ 6 h/day for at least 5 continuous or discontinuous years. The mean duration was 12.2 years. The control group had been exposed for a maximum of 3 continuous or discontinuous months. The mean ages for the experimental and control groups were 43.1 and 44.3 years, respectively. There were no differences in the distributions and types of dysfunctional measurements observed between exposed and non-exposed groups. There were no differences in the mean percentage of predicted pulmonary function values between exposed and non-exposed groups. None of the x-rays showed signs of pneumoconiosis or fibrosis.

Silica

The Occupational Safety and Health Administration (OSHA) permissible exposure limit (PEL) to amorphous Silica is 80 mg/m³ or 20 million particles per cubic foot air averaged over an 8-h work shift.⁸⁶ The National Institute for Occupational Safety and Health recommended exposure limit (REL) for amorphous Silica is 6 mg/m³.

Workers (n = 215) with exposure to Silica between 1947 and 1959 were studied using chest x-rays.⁸⁷ Exposure ranged from 15 to 100 mg/m³, 2 to 6 mg/m³, and 3 to 7 mg/m³, depending on workstation. Hairline actuation of the interlobar fissures, suggesting slight interlobar pleuritis, was the only remarkable sign. There were no signs of silicosis.

In an unpublished study, 29 workers in a silicone products manufacturing plant were surveyed.¹⁵ Silica exposure ranged from 0.15 to 10 mg/m³, with a mean of 1.7 mg/m³. Ten of 15 workers in the room temperature vulcanizing rubber area complained of upper respiratory tract irritation. Some of the workers in the heat curable rubber compounding area, where the potential exposure to Silica was greater, complained about eye irritation, nausea, headaches, or rashes; none reported upper or lower respiratory problems.

Workers (n = 200) with intensive and regular contact with Silica from 1972 to 2000 were evaluated.¹⁴ There was no evidence of skin allergy caused by the Silica. There were signs of irritation attributed to the desiccative and defatting properties of Silica, which resulted in skin dryness; this effect could be controlled by regular use of skin-protection ointment.

An occupational study of 143 workers exposed to Silica from 1959 to 1985 was performed.¹⁴ Exposure ranged from 1 to 34 years. There were complaints of abnormalities in lung function or histology in 54/143 (36%) of the workers (no further details available). Dry cough, expectoration or dyspnea was reported in 34/54 of these workers. A total of 42/54 (78%) of these workers had some possible confounding factor (i.e., smoking). Radiological examination did not show any signs of fibrotic disease. Spirometric examination showed obstructive and/or restrictive ventilation disturbances in 24 workers. Most of the adverse findings were associated with the confounding factors.

In an unpublished occupational exposure study, x-rays were taken of 99 workers who had manufactured Silica for various amounts of time.¹⁴ The x-rays revealed no evidence of any occupational disease, including silicosis.

SUMMARY

This report assesses the safety of amorphous Silica and 23 synthetically-manufactured silicate ingredients as used in cosmetics. The majority of these ingredients function as abrasives, absorbents, bulking agents, and/or deodorant agents in cosmetic products. The Panel previously reviewed the safety of Aluminum Silicate, Calcium Silicate, Magnesium Silicate, Magnesium Trisilicate, Sodium Magnesium Silicate, Zirconium Silicate, Lithium Magnesium Silicate, and Lithium Magnesium Sodium Silicate in a report that was published in 2003. The Panel concluded that these ingredients were safe as used in cosmetic products. In accordance with its procedures, the Panel evaluates the conclusions of previously-issued reports every 15 years, and it has been at least 15 years since this assessment has been issued. This report has been reopened to add additional ingredients, including several that were also previously reviewed. A report on Potassium Silicate, Sodium Metasilicate, and Sodium Silicate was published in 2005 with the conclusion that these ingredients were safe for use in cosmetic products in the practices of use and concentration described in the safety assessment when formulated to avoid irritation. A report on Silica, Alumina Magnesium Metasilicate (now called Magnesium Aluminometasilicate), Aluminum Iron Silicates, Hydrated Silica, and Sodium Potassium Aluminum Silicate was finalized by the Panel in 2009, with the conclusion that these ingredients are safe as cosmetic ingredients in the practices of use and concentrations as described in the safety assessment.

The Panel considered the method of manufacture of these ingredients (whether synthetic or mined) to be of significant importance to this assessment. Thus, the current assessment is exclusive to the ingredients herein when manufactured via synthetic methods.

According to 2019 VCRP data, Silica has the most reported uses in cosmetic products, with a total of 8222; the majority of the uses are in leave-on makeup preparations and eye makeup preparations. Hydrated Silica has the second most reported uses in cosmetic products, with a total of 462; the majority of the uses are in rinse-off oral hygiene and personal cleanliness products. The reported numbers of uses for the remaining ingredients in this report are much lower. The uses for both of these ingredients have increased since the original safety assessments were finalized: in 2009, Silica was reported to have 3276 uses and Hydrated Silica was reported to have 176 uses. The results of the concentration of use survey conducted in 2018 by the Council indicate Silica has the highest reported maximum concentration of use; it is used at up to 82% in face and neck products and 50% in mascaras. Hydrated Silica is used at up to 33.8% in oral hygiene products and at up to 10% in leave-on skin care products. According to the original safety assessment, the maximum use concentration in 2008 for Silica was 44% in eye shadows. The maximum use concentration for Hydrated Silica in 2008 was 34% in dentifrices; the maximum leave-on concentration was 4% in face powders.

Hydrated Silica in water had a dermal LD₅₀ greater than 5 g/kg in rabbits; Potassium Silicate (30% solution in water) had a dermal LD₅₀ greater than 5 g/kg in rats. In oral rat studies, LD₅₀s of > 2 g/kg Aluminum Silicate (concentration not stated), > 10 g/kg Calcium Silicate (20%), 40 g/kg Hydrated Silica (26% in water), > 5 g/kg Potassium Silicate (concentration not stated), > 10 g/kg Silica (in stock diet 1:4 w/w), > 2 g/kg Sodium Magnesium Aluminum Silicate (concentration not stated), and up to 8.65 g/kg Sodium Silicate were reported. An oral LD₅₀ for Sodium Silicate in mice was 6.60 g/kg. In inhalation studies that ranged in duration from 1 to 6 hours, the LC₅₀s for Hydrated Silica (30% SiO₂), Potassium Silicate (30%), and Silica (concentration not reported) in rats were > 3300 mg/m³, > 2060 mg/m³, and > 191,300 mg/m³, respectively.

No adverse effects were reported in a 3-week dermal study of Silica (up to 10 g/kg/d) in rabbits. In short-term oral studies, the NOAEL for Hydrated Silica was > 24.2 g/kg/day in a 14-day dietary study in rats. The NOEL was 500 mg/kg/d in a 5- to 8-week dietary study in rats that were fed up to 16,000 mg/kg/d Silica. In subchronic oral studies, the NOEL was 4000 mg/kg/day in a 13-week dietary study in rats fed Hydrated Silica at up to 4000 mg/kg/d. No clinical signs of toxicity or gross or microscopic changes were reported in a 13-week dietary study in rats that received up to 3500 mg/kg/d Silica. In oral chronic studies, lower liver weights in female rats without significant findings at histopathological examinations was observed in a 103-week dietary study of up to 5% Hydrated Silica in rats, but no remarkable findings were observed by the same researchers of the same material in a 93-week dietary study in mice. The NOAEL in a 6-month dietary rat study of up to 10% Hydrated Silica was 8980 mg/kg/d. No remarkable findings were reported in 6-month dietary studies of up to 10% Silica in rats, although there were reduced liver and prostate weights and increased numbers of leukocytes and eosinophils in female and male rats, respectively, in another 6-month study at up to 3 g Silica/week.

In short-term inhalation studies with Hydrated Silica, inflammatory and pulmonary lesions were observed in rats at 30 mg/m³. Inflammatory responses were also observed in rats exposed to Silica in studies that lasted between 5 to 14 days. No significant lung histopathological findings or adverse changes in inflammatory markers were observed in rats that were exposed to nanoparticle Silica (particle size 50-79 nm; concentrations 0.4-5.4 mg/m³) for 4 weeks. In subchronic inhalation studies, inflammatory responses were noted in the lungs and lymph nodes along with pulmonary lesions after exposure to Hydrated Silica at 35 mg/m³ (particle and agglomerate/aggregate size 1 to ~120 µm). In a 13-week inhalation study of Silica in rats, the NOEL was 1.3 mg/m³. Inflammation and pulmonary lesions, including fibrosis, were noted in this study and another 13-week rat study. In inhalation studies of 9- to 12-month duration, Hydrated Silica caused pulmonary inflammation and emphysema in rats exposed to 25 to 85 mg/m³. The LOAEC in rabbits exposed for 9 months to Hydrated Silica was 28 mg/m³. No silicotic processes were noted in studies of rabbits, rats, and guinea pigs exposed to an average of 126 mg/m³ Hydrated Silica for 12, 15, and 24 months, respectively. No neoplasia was observed. In a 12-month study with Hydrated Silica and Silica in rats, the LOAEC was 6 to 9 mg/m³ due to interstitial fibrosis. The same test materials also were associated with nodular fibrosis in an 18-month study with monkeys. The LOAEC in a 6-month rat inhalation study with Silica was 53 mg/m³. Emphysema and fibrosis were noted around 4 months of exposure. Inflammatory responses and pulmonary lesions were noted in rat, guinea pigs, rabbits, and monkeys in studies up to 24 months in duration.

Aluminum Silicate, Hydrated Silica, Silica, Sodium Metasilicate, Sodium Silicate, and Zinc Silicate were not genotoxic in Ames tests, HGPRT gene mutation assays, or chromosome aberration tests. Genotoxicity studies of Hydrated Silica at up to 5000 mg/kg in mice and rats were negative.

Carcinogenic effects were not reported in oral studies of Hydrated Silica in mice or Silica in rats. An inhalation study of Hydrated Silica in mice and an intratracheal study of Silica in rats also were negative for carcinogenicity.

Aluminum Silicate and Zinc Silicate were predicted to be not irritating in EpiDermTM skin assays. In rabbit studies, the irritation potential of Potassium Silicate (up to 36%) and Sodium Metasilicate (up to 97%) were dependent on concentration. Very slight to no irritation was observed dermal irritation studies in rabbits with Hydrated Silica (at up to 50% solution in olive oil) and Silica (up to 12% solution in methyl ethyl cellulose). Aluminum Silicate (up to 25%) and Zinc Silicate (up to 50%) were not sensitizing in LLNA studies. Potassium Silicate (30%) and Hydrated Silica (20%) was not sensitizing in guinea pig sensitization tests. Hydrated Silica (up to 45%) and Silica (21.74% in formulation) were not sensitizing in HRIPT.

Aluminum Silicate (tested pure) was predicted to be not irritating using the HET-CAM method. Sodium Metasilicate (concentration not reported) was predicted to be corrosive in an in vitro method using rabbit eyes, and Zinc Silicate (20%) was predicted to be irritating in a BCOP test. Potassium Silicate was not irritating to slightly irritating when tested at up to 35% in rabbit eyes. Hydrated Silica (concentration not provided) and Silica were not irritating to slight irritating in rabbit eyes.

Case reports of severe injury were reported from ingestion and inhalation of Sodium Metasilicate. Workers in environments with aerosolized Silica had few signs of silicosis or pulmonary disease up to 100 mg/m³. Smoking and exposure to Silica synergize to induce small airway disease. Exposure to Hydrated Silica also had no evidence of silicosis or pulmonary disease. There were signs of dermal irritation due to the desiccative and defatting properties of Silica.

DISCUSSION

The Panel assessed the safety of amorphous Silica and 23 synthetically-manufactured silicate ingredients; 16 of these ingredients were previously reviewed by the Panel, and 8 are reviewed herein for the first time. The Panel considered the method of manufacture of these ingredients (whether synthetic or mined) to be of significant importance when reviewing safety. The Panel emphasized that this report reviews only the safety of synthetic amorphous Silica and silicate ingredients. Crystalline silica and mined silicates are not toxicologically similar to amorphous silica and would need to be reviewed separately.

Data were sufficient to assess the safety of two of the 24 ingredients (i.e., Silica and Hydrated Silica) included in this report. Specifically, the Panel reviewed the current safety test data on amorphous Silica and Hydrated Silica and determined that these two ingredients do not pose an inhalation safety risk. The exposures that were tested in inhalation studies were at much higher concentrations than those possible with cosmetic use, and had very few adverse effects. Aggregation of Silica and Hydrated Silica particles in cosmetic formulations reduces potential inhalation exposure. While the Panel noted the effects on trachea-bronchial lymph nodes in mice, the carcinogenicity study used such high concentrations of Hydrated Silica that the effects were due to the overload of the animal system; therefore, concern over incidental inhalation of Silica in cosmetics was mitigated.

The Panel was concerned that the potential exists for dermal and ocular irritation with the use of products formulated using synthetic amorphous Silica and silicate ingredients. Therefore, the Panel specified that products containing Silica and synthetically-manufactured amorphous silicates must be formulated to be non-irritating.

Data on the remaining ingredients were considered insufficient to determine safety. The additional data needed for the 22 silicate ingredients comprise:

- Chemical characterization (structure), composition, and impurities data for the silicate ingredients
- Method of manufacturing and/or source data for the silicate ingredients.
 - Depending on the information provided, additional data on toxicological endpoints may be needed.

CONCLUSION

The Panel concluded that **Silica** and **Hydrated Silica** are safe in the present practices of use and concentration described in the safety assessment when formulated to be non-irritating. The Panel further concluded that the available data were insufficient to make a determination that of the following 22 ingredients are safe under the intended conditions of use in cosmetic formulations.

Aluminum Iron Calcium Magnesium Germanium Silicates*

Aluminum Iron Calcium Magnesium Zirconium Silicates*

Aluminum Iron Silicates*

Aluminum Silicate

Ammonium Silver Zinc Aluminum Silicate

Calcium Magnesium Silicate*

Calcium Silicate

Lithium Magnesium Silicate

Lithium Magnesium Sodium Silicate

Magnesium Aluminometasilicate

Magnesium Silicate

Magnesium Trisilicate

Potassium Silicate

Sodium Magnesium Aluminum Silicate*

Sodium Magnesium Silicate

Sodium Metasilicate

Sodium Potassium Aluminum Silicate

Sodium Silicate

Sodium Silver Aluminum Silicate*

Tromethamine Magnesium Aluminum Silicate*

Zinc Silicate*

Zirconium Silicate*

*Ingredients in **red** were previously reviewed by the Panel.*

**No reported uses.*

FIGURES




Figure 1. Process for the manufacture of Silica (pyrogenic form).

TABLES

Table 1. Definitions and functions of the ingredients in this safety assessment.⁴

Ingredient & CAS No.	Definition	Function(s)
Aluminum Iron Calcium Magnesium Germanium Silicates	Aluminum Iron Calcium Magnesium Germanium Silicates is a ceramic powder consisting mainly of silicon dioxide, aluminum oxide, ferric oxide, calcium oxide, magnesium oxide and germanium oxide.	Anticaries Agents; Antifungal Agents; Antimicrobial Agents; Antioxidants
Aluminum Iron Calcium Magnesium Zirconium Silicates	Aluminum Iron Calcium Magnesium Zirconium Silicates is a ceramic powder consisting mainly of silicon dioxide, aluminum oxide, ferric oxide, calcium oxide, magnesium oxide and zirconium oxide.	Bulking Agents
Aluminum Iron Silicates	Aluminum Iron Silicates is a ceramic powder consisting mainly of silicon dioxide, aluminum oxide, and ferric oxide.	Abrasives; Bulking Agents
Aluminum Silicate 1327-36-2	Aluminum Silicate is a complex inorganic salt that has a composition consisting generally of 1 mole of alumina and 1 to 3 moles of silica.	Abrasives; Absorbents; Anticaking Agents; Bulking Agents; Opacifying Agents; Slip Modifiers
Ammonium Silver Zinc Aluminum Silicate	Ammonium Silver Zinc Aluminum Silicate is a complex silicate formed from the reaction of zinc nitrate, Ammonium Nitrate, and Silver Nitrate with zeolite.	Absorbents; Deodorant Agents; Preservatives
Calcium Magnesium Silicate 12765-06-9	Calcium Magnesium Silicate is a synthetic silicate clay consisting chiefly of calcium and magnesium silicates	Absorbents; Deodorant Agents
Calcium Silicate 1344-95-2	Calcium Silicate is a hydrous or anhydrous silicate with varying proportions of calcium oxide and silica.	Absorbents; Bulking Agents; Opacifying Agents
Hydrated Silica 10279-57-9 112926-00-8 1343-98-2 (silicic acid) 63231-67-4 7631-86-9	Hydrated Silica is the inorganic oxide that conforms generally to the formula $\text{SiO}_2 \cdot x\text{H}_2\text{O}$.	Abrasives; Absorbents; Anticaking Agents; Bulking Agents; Opacifying Agents; Oral Care Agents; Skin-Conditioning Agents – Misc.; Viscosity Increasing Agents - Aqueous
Lithium Magnesium Silicate 37220-90-9	Lithium Magnesium Silicate is a synthetic silicate clay consisting mainly of lithium and magnesium silicates.	Binders; Bulking Agents; Viscosity Increasing Agents - Aqueous
Lithium Magnesium Sodium Silicate 53320-86-8	Lithium Magnesium Sodium Silicate is a synthetic silicate clay consisting mainly of lithium, magnesium and sodium silicates.	Bulking Agents; Viscosity Increasing Agents - Aqueous
Magnesium Aluminometasilicate 12408-47-8	Magnesium Aluminometasilicate is the inorganic compound consisting of varying amounts of magnesium oxide, aluminum oxide and silica.	Absorbents; Anticaking Agents; Bulking Agents; Opacifying Agents; Slip Modifiers; Viscosity Increasing Agents – Aqueous; Viscosity Increasing Agents – Nonaqueous
Magnesium Silicate 1343-88-0	Magnesium Silicate is an inorganic salt of variable composition which consists mainly of $\text{MgO} \cdot \text{SiO}_2 \cdot x\text{H}_2\text{O}$.	Absorbents; Anticaking Agents; Bulking Agents; Opacifying Agents; Slip Modifiers; Viscosity Increasing Agents - Aqueous
Magnesium Trisilicate 14987-04-3	Magnesium Trisilicate is the inorganic compound that conforms generally to the formula $2\text{MgO} \cdot 3\text{SiO}_2 \cdot x\text{H}_2\text{O}$.	Abrasives; Absorbents; Anticaking Agents; Bulking Agents; Opacifying Agents; Slip Modifiers; Viscosity Increasing Agents - Aqueous
Potassium Silicate 1312-76-1	Potassium Silicate is a potassium salt of silicic acid.	Corrosion Inhibitors
Silica 112945-52-5 60676-86-0 7631-86-9	Silica is the inorganic oxide that conforms to the formula SiO_2 .	Abrasives; Absorbents; Anticaking Agents; Bulking Agents; Dispersing Agents – Nonsurfactant; Opacifying Agents
Sodium Magnesium Silicate	Sodium Magnesium Silicate is a synthetic silicate clay with a composition mainly of magnesium and sodium silicate.	Binders; Bulking Agents
Sodium Magnesium Aluminum Silicate 12040-43-6	Sodium Magnesium Aluminum Silicate is the complex silicate obtained by the reaction of Sodium Silicate and Sodium Aluminate in an aqueous solution of Magnesium Nitrate.	Absorbents
Sodium Metasilicate 6834-92-0	Sodium Metasilicate is the inorganic salt that conforms to the formula Na_2SiO_3 .	Chelating Agents; Corrosion Inhibitors
Sodium Potassium Aluminum Silicate 12736-96-8; 66402-68-4	Sodium Potassium Aluminum Silicate is a complex silicate refined from naturally occurring minerals, or derived synthetically.	Bulking Agents
Sodium Silicate 1344-09-8	Sodium Silicate is a sodium salt of silicic acid.	Buffering Agents; Corrosion Inhibitors; pH Adjusters
Sodium Silver Aluminum Silicate	Sodium Silver Aluminum Silicate is the complex silicate obtained by the reaction of sodium silicate with sodium aluminate in an aqueous solution of sodium nitrate, sodium hydroxide and silver nitrate.	Absorbents; Deodorant Agents

Table 1. Definitions and functions of the ingredients in this safety assessment.⁴

Ingredient & CAS No.	Definition	Function(s)
Tromethamine Magnesium Aluminum Silicate	Tromethamine Magnesium Aluminum Silicate is a reaction product of Tromethamine and Magnesium Aluminum Silicate.	Viscosity Increasing Agents - Aqueous
Zinc Silicate 13597-65-4	Zinc Silicate is an inorganic salt consisting of variable amounts of zinc oxide and silica.	Deodorant Agents
Zirconium Silicate 10101-52-7 1344-21-4	Zirconium Silicate is the inorganic compound that conforms to the formula $ZrSiO_4$.	Abrasives; Opacifying Agents

Table 2. Physical and chemical properties

Property	Value	Reference
Aluminum Silicate		
Physical Form	Light brown to brown, odorless beads	11
Formula Weight (Da)	162.05 - 426.05	1
Density (g/ml @ 20°C)	3.156; 3.247	1
Calcium Silicate		
Physical Form	White or slightly cream-colored free-flowing powder	1
Formula Weight (Da)	116.16	1
Density (g/ml @ 25°C)	0.227	12
Melting Point (°C)	1710	12
Water Solubility (mg/l @ 20°C)	260	12
Magnesium Silicate		
Physical Form	Fine, white, odorless, tasteless powder, free from grittiness	1
Magnesium Trisilicate		
Physical Form	Fine, white, odorless, tasteless powder, free from grittiness	1
Potassium Silicate		
Physical Form	Yellowish to colorless, translucent to transparent, hygroscopic	2
Density (g/ml @ 20°C)	1.26-1.60	8
Vapor Pressure (mmHg @ 1175°C)	0.00772	8
Melting Point (°C)	905	8
Silica		
Physical Form	White fluffy powder	25
Formula Weight (Da)	60.1	88
Density (g/ml @ 20°C)	2.2	14
Specific Gravity (g/ml)	2.65	86
Vapor Pressure (mmHg)	0	86,88
Melting Point (°C)	~1700-1710	14,86,88
Boiling Point (°C)	2230	88
Water Solubility (mg/l @ 20°C)	15-68	14
pH	4-9	14
Sodium Magnesium Silicate		
pH	8.5-10.5 (2% aqueous dispersion)	1
Sodium Magnesium Aluminum Silicate		
Physical Form	White powder	7
Density (g/ml @ 20°C)	2.11	7
Melting Point (°C)	> 400	7
Water Solubility (mg/l @ 20°C)	2.24	7
Sodium Metasilicate		
Physical Form	Nonahydrate, efflorescent platelets	2
Formula Weight (Da)	122.08	2
Density (g/ml)	2.614	2
Vapor Pressure (mmHg @ 1175°C)	0.00772	9
Melting Point (°C)	1089	2
Water Solubility (g/l @ 20 °C)	210	9
pH	12 (0.1% solution)	2
Sodium Silicate		
Physical Form	Colorless to white or grayish-white, crystal-like clumps or aqueous solutions	2
Density (g/ml)	1.26 - 1.71	10
Vapor Pressure (mmHg)	0.00120	10
Melting Point (°C)	730 - 870	10
Water Solubility (mg/l @ 20 °C)	115	10
Acidity/Alkalinity	Strongly alkaline	2
Zinc Silicate		
Physical Form	White crystals or white powder	45,46
Formula Weight (Da)	222.90	46
Density (g/ml)	4.103	45
Melting Point (°C)	1509	45
Water Solubility (µg/l @ 20 °C)	162.01	6
Zirconium Silicate		
Physical Form	Bipyramidal crystals, colorless unless has impurities and radioactive bombardment; red or various colored crystals	1
Formula Weight (Da)	183.31	1
Density (g/ml)	4.56	1
pH	6-7.5 (10% aqueous slurry)	1

Table 3. Current and historical frequency and concentration according to duration and type of exposure for previously reviewed silicates.^{1-3,27}

	Aluminum Silicate				Calcium Silicate			
	# of Uses		Max Conc of Use (%)		# of Uses		Max Conc of Use (%)	
	2019	1998	2018	1999	2019	1998	2018	1999
Totals*	63	10	2.8-4.6	0.5-37	62	132	0.00013-20	0.3-10
Leave-On	41	6	NR	0.5-3	52	115	0.00013-5	0.3-10
Rinse-Off	22	4	2.8-4.6	2-37	1	1	1.5-20	8
Diluted for (Bath) Use	NR	NR	NR	NR	9	16	0.86-1.3	NR
Eye Area	2	2	NR	0.5	4	11	1	1-8
Incidental Ingestion	NR	NR	NR	37	NR	3	0.00013	0.5
Incidental Inhalation-Spray	1; 11 ^a ; 23 ^b	1 ^a	NR	NR	1 ^a ; 1 ^b	NR	0.005	NR
Incidental Inhalation-Powder	23 ^b	NR	NR	NR	25; 1 ^b	75	0.25-5; 4.7-5 ^c	0.3-10
Dermal Contact	59	8	2.8-4.6	2-3	61	128	0.25-20	0.3-10
Deodorant (underarm)	NR	NR	NR	NR	NR	NR	NR	NR
Hair - Non-Coloring	3	NR	NR	NR	NR	NR	1.5	NR
Hair-Coloring	1	NR	NR	NR	NR	NR	0.005	NR
Nail	NR	NR	NR	NR	1	1	NR	NR
Mucous Membrane	3	NR	4.6	37	9	19	0.00013-1.3	0.5
Baby Products	NR	NR	NR	NR	NR	NR	NR	NR
	Hydrated Silica				Lithium Magnesium Silicate			
	# of Uses		Max Conc of Use (%)		# of Uses		Max Conc of Use (%)	
	2019*	2009	2018	2008	2019	1998	2018	1999
Totals*	462	176	0.00001-33.8	0.001-34	2	NR	0.3-5	NR
Leave-On	171	90	0.0002-10	0.001-4	2	NR	0.3-5	NR
Rinse-Off	283	78	0.00001-33.8	0.01-34	NR	NR	NR	NR
Diluted for (Bath) Use	8	8	0.3-12	0.4-4	NR	NR	NR	NR
Eye Area	9	8	0.001-5.8	0.06-2	NR	NR	NR	NR
Incidental Ingestion	81	25	0.17-33.8	0.003-34	2	NR	NR	NR
Incidental Inhalation-Spray	16 ^a ; 10 ^b	10 ^a ; 12 ^b	0.45-0.9; 8.9-23.7 ^a	0.04-2 ^a ; 0.06-2 ^b	NR	NR	0.4; 0.3 ^a	NR
Incidental Inhalation-Powder	33; 10 ^b	33; 12 ^b	1; 0.0012-10 ^c	2-4; 0.06-2 ^b	NR	NR	5 ^c	NR
Dermal Contact	349	117	0.0002-16	0.001-17	NR	NR	0.4-5	NR
Deodorant (underarm)	1 ^a	NR	0.066	2 ^a	NR	NR	NR	NR
Hair - Non-Coloring	4	NR	0.00001-8.9	0.04-2	NR	NR	0.3	NR
Hair-Coloring	10	20	1.9-8.9	2	NR	NR	NR	NR
Nail	15	13	0.75-5.5	1-2	NR	NR	NR	NR
Mucous Membrane	250	50	0.0051-33.8	0.003-34	2	NR	NR	NR
Baby Products	NR	NR	0.0041-0.005	NR	NR	NR	NR	NR

Table 3. Current and historical frequency and concentration according to duration and type of exposure for previously reviewed silicates.^{1-3,27}

	Lithium Magnesium Sodium Silicate				Magnesium Aluminometasilicate			
	# of Uses		Max Conc of Use (%)		# of Uses		Max Conc of Use (%)	
	2019	1998	2018	1999	2019	2009	2018	2008
Totals*	53	NR	0.0005-6	NR	4	NR	NR	0.002-0.01
<i>Leave-On</i>	32	NR	0.0005-6	NR	3	NR	NR	0.002-0.01
<i>Rinse-Off</i>	21	NR	0.4	NR	1	NR	NR	NR
<i>Diluted for (Bath) Use</i>	NR	NR	NR	NR	NR	NR	NR	NR
Eye Area	9	NR	0.0005-4	NR	1	NR	NR	NR
Incidental Ingestion	NR	NR	NR	NR	NR	NR	NR	NR
Incidental Inhalation-Spray	4 ^a ; 2 ^b	NR	6 ^a	NR	1 ^b	NR	NR	0.002-0.01 ^b
Incidental Inhalation-Powder	2 ^b	NR	3 ^c	NR	1 ^b	NR	NR	0.002-0.01 ^b
Dermal Contact	34	NR	0.0005-4	NR	3	NR	NR	0.002-0.01
Deodorant (underarm)	NR	NR	0.5	NR	NR	NR	NR	NR
Hair - Non-Coloring	12	NR	6	NR	NR	NR	NR	NR
Hair-Coloring	NR	NR	NR	NR	NR	NR	NR	NR
Nail	3	NR	NR	NR	NR	NR	NR	NR
Mucous Membrane	NR	NR	NR	NR	NR	NR	NR	NR
Baby Products	NR	NR	NR	NR	NR	NR	NR	NR
	Magnesium Silicate				Magnesium Trisilicate			
	# of Uses		Max Conc of Use (%)		# of Uses		Max Conc of Use (%)	
	2019	1998	2018	1999	2019	1998	2018	1999
Totals*	78	NR	0.001-21.6	NR	17	NR	NR	NR
<i>Leave-On</i>	76	NR	0.001-21.6	NR	NR	NR	NR	NR
<i>Rinse-Off</i>	2	NR	NR	NR	17	NR	NR	NR
<i>Diluted for (Bath) Use</i>	NR	NR	NR	NR	NR	NR	NR	NR
Eye Area	30	NR	3-21.6	NR	NR	NR	NR	NR
Incidental Ingestion	16	NR	10	NR	NR	NR	NR	NR
Incidental Inhalation-Spray	2 ^a ; 2 ^b	NR	NR	NR	NR	NR	NR	NR
Incidental Inhalation-Powder	5; 2 ^b	NR	1 ^c	NR	NR	NR	NR	NR
Dermal Contact	60	NR	0.001-21.6	NR	16	NR	NR	NR
Deodorant (underarm)	NR	NR	NR	NR	NR	NR	NR	NR
Hair - Non-Coloring	NR	NR	NR	NR	NR	NR	NR	NR
Hair-Coloring	NR	NR	NR	NR	1	NR	NR	NR
Nail	1	NR	NR	NR	NR	NR	NR	NR
Mucous Membrane	16	NR	10	NR	NR	NR	NR	NR
Baby Products	NR	NR	NR	NR	NR	NR	NR	NR

Table 3. Current and historical frequency and concentration according to duration and type of exposure for previously reviewed silicates.^{1-3,27}

	Potassium Silicate				Silica***			
	# of Uses		Max Conc of Use (%)		# of Uses		Max Conc of Use (%)	
	2019	2001	2018	1999/2000	2019	2009	2018	2008
Totals*	1	2	NR	NR	8222	3276	0.000005-82	0.0000003-44
<i>Leave-On</i>	NR	1	NR	NR	7499	2937	0.0001-82	0.00004-44
<i>Rinse-Off</i>	1	1	NR	NR	669	316	0.000005-21	0.0000003-16
<i>Diluted for (Bath) Use</i>	NR	NR	NR	NR	54	23	0.1-4	0.02-2
Eye Area	NR	NR	NR	NR	2348	867	0.00068-50	0.0004-44
Incidental Ingestion	NR	NR	NR	NR	1565	551	0.014-50	0.01-21
Incidental Inhalation-Spray	NR	NR	NR	NR	166; 516 ^a ; 419 ^b	19; 247 ^a ; 183 ^b	0.0001-2; 0.0042-14 ^a ; 0.5-1 ^b	0.0005-6; 0.00004-8 ^a ; 0.02-10 ^b
Incidental Inhalation-Powder	NR	NR	NR	NR	520; 419 ^b ; 3 ^c	248; 183 ^b ; 1 ^c	0.016-66; 0.5-1 ^b ; 0.08-82 ^c	1-26; 0.02-10 ^b
Dermal Contact	1	1	NR	NR	5416	2298	0.0001-82	0.0000003-44
Deodorant (underarm)	NR	NR	NR	NR	31 ^a	38 ^a	0.0001-10.4 ^d	0.02-9 ^a
Hair - Non-Coloring	NR	1	NR	NR	142	51	0.000005-4	0.0005-3
Hair-Coloring	NR	NR	NR	NR	233	149	0.0005-10	0.002-6
Nail	NR	NR	NR	NR	559	92	0.2-10	0.3-9
Mucous Membrane	NR	NR	NR	NR	1834	624	0.0005-50	0.0000003-21
Baby Products	NR	NR	NR	NR	7	2	0.0006-3	0.003-10
	Sodium Magnesium Silicate				Sodium Metasilicate			
	# of Uses		Max Conc of Use (%)		# of Uses		Max Conc of Use (%)	
	2019	1998	2018	1999	2019	2001	2018	1999/2000
Totals*	99	34	0.13-0.2	0.08-5	133	191	0.001-15	13-18
<i>Leave-On</i>	65	33	0.13	0.08-5	4	NR	0.001	NR
<i>Rinse-Off</i>	33	1	0.2	0.3-5	129	191	1.2-15	13-18
<i>Diluted for (Bath) Use</i>	1	NR	NR	NR	NR	NR	0.1	NR
Eye Area	13	13	NR	0.08-0.4	NR	NR	NR	NR
Incidental Ingestion	9	1	NR	0.3-3	NR	NR	NR	NR
Incidental Inhalation-Spray	17 ^a ; 5 ^b	2 ^a ; 5 ^b	NR	1-5 ^a ; 0.1-5 ^b	1 ^a ; 1 ^b	NR	NR	NR
Incidental Inhalation-Powder	7; 5 ^b	4; 5 ^b	NR	0.4; 0.1-5 ^b	1 ^b	NR	NR	NR
Dermal Contact	87	31	0.13-0.2	0.08-5	1	2	0.001-1.2	NR
Deodorant (underarm)	NR	NR	NR	0.5 ^a	NR	NR	NR	NR
Hair - Non-Coloring	2	1	NR	NR	3	1	NR	NR
Hair-Coloring	NR	NR	NR	NR	129	188	5-15	13-18 ^c
Nail	NR	NR	NR	NR	NR	NR	NR	NR
Mucous Membrane	13	1	NR	0.3	NR	NR	0.1	NR
Baby Products	NR	NR	NR	NR	NR	NR	NR	NR

Table 3. Current and historical frequency and concentration according to duration and type of exposure for previously reviewed silicates.^{1-3,27}

	Sodium Potassium Aluminum Silicate				Sodium Silicate			
	# of Uses		Max Conc of Use (%)		# of Uses		Max Conc of Use (%)	
	2019	2009	2018	2008	2019	2001	2018	1999/2000
Totals*	18	1	0.36-1.1	0.001-4	90	22	0.017-35	0.06-55
<i>Leave-On</i>	16	NR	0.36-1.1	0.001-4	16	2	NR	0.6-1
<i>Rinse-Off</i>	2	1	NR	NR	74	20	0.017-35	0.06-55
<i>Diluted for (Bath) Use</i>	NR	NR	NR	NR	NR	NR	NR	NR
Eye Area	NR	NR	1.1	NR	4	1	NR	NR
Incidental Ingestion	NR	NR	NR	NR	2	NR	0.44	0.6
Incidental Inhalation-Spray	8 ^a	NR	NR	NR	1 ^a , 5 ^b	1 ^b	NR	NR
Incidental Inhalation-Powder	NR	NR	0.36 ^c	NR	5 ^b	1 ^b	NR	NR
Dermal Contact	18	1	0.36-1.1	NR	34	14	0.017-1.5	0.06-10
Deodorant (underarm)	NR	NR	NR	NR	NR	NR	NR	NR
Hair - Non-Coloring	NR	NR	NR	NR	3	NR	NR	NR
Hair-Coloring	NR	NR	NR	NR	51	8	15-35	1-55 ^f
Nail	NR	NR	NR	0.001-4	NR	NR	NR	NR
Mucous Membrane	1	NR	NR	NR	9	2	0.44-1.4	0.06-7
Baby Products	NR	NR	NR	NR	NR	NR	NR	0.6

NR = Not reported.

† Because each ingredient may be used in cosmetics with multiple exposure types, the sum of all exposure types may not equal the sum of total uses.

^a. It is possible these products may be sprays, but it is not specified whether the reported uses are sprays.

^b. Not specified whether a powder or a spray, so this information is captured for both categories of incidental inhalation.

^c. It is possible these products may be powders, but it is not specified whether the reported uses are powders.

^d. Concentration of use in aerosol deodorants reported to be 0.0001% - 0.084%.

^e. Hair bleaches were diluted from 13% -18% to 7% -14% before use.

^f. Hair bleaches were diluted from 16%-55% to 1%-20% before use.

*Includes entries for Hydrated Silica and Silicic Acid from the VCRP database.

*** Includes entries for Silica; Silica, Amorphous; Silica, Fumed; and Silicon Dioxide, Colloidal from the VCRP database.

Table 4. Frequency (2019) and concentration (2018) of use according to duration and type of exposure for Silicate add-on ingredients²⁷⁻²⁹

	# of Uses	Max Conc of Use (%)
	Ammonium Silver Zinc Aluminum Silicate	
Totals[†]	32	0.001
Duration of Use		
Leave-On	31	NR
Rinse Off	1	0.001
Diluted for (Bath) Use	NR	NR
Exposure Type		
Eye Area	24	NR
Incidental Ingestion	NR	NR
Incidental Inhalation-Spray	NR	NR
Incidental Inhalation-Powder	2	NR
Dermal Contact	32	0.001
Deodorant (underarm)	NR	NR
Hair - Non-Coloring	NR	NR
Hair-Coloring	NR	NR
Nail	NR	NR
Mucous Membrane	NR	NR
Baby Products	NR	NR

NR = Not reported.

[†] Because each ingredient may be used in cosmetics with multiple exposure types, the sum of all exposure types may not equal the sum of total uses.**Table 5. Ingredients not reported to be in use.²⁷⁻²⁹**

Aluminum Iron Calcium Magnesium Germanium Silicates

Aluminum Iron Calcium Magnesium Zirconium Silicates

Aluminum Iron Silicates*

Calcium Magnesium Silicate

Sodium Magnesium Aluminum Silicate

Sodium Silver Aluminum Silicate

Tromethamine Magnesium Aluminum Silicate

Zinc Silicate

Zirconium Silicate*

*Additionally, no uses were reported in original safety assessment.

Table 6.. Acute toxicity studies

Ingredient/Concentration/Vehicle	Dose/Study Protocol	Results	LD ₅₀ or LC ₅₀	Reference
Dermal				
Hydrated Silica; no further details	2000 mg/kg bw applied to intact and abraded skin for 24 h; 10 New Zealand white rabbits; no further details	Details not provided	> 2000 mg/kg	14,15
Hydrated Silica; in water	2000, 3000, 4000, or 5000 mg/kg in groups of 4 New Zealand white rabbits; 2 rabbits in each group had abraded skin; test site was covered with occlusive patch for 24 h; no further details	Very slight erythema; no systemic signs of toxicity or organ toxicity	> 5000 mg/kg	14,15
30% Potassium Silicate solution in water; molar ratio = 2.47	5000 mg/kg bw applied for 24 h to 5 male and 5 female Sprague-Dawley rats; test sites were occluded	Erythema and alopecia noted at application site of 4 females and 1 male between days 1 and 8; no other adverse effects during observation period or necropsy	> 5000 mg/kg	8
Oral				
Aluminum Silicate in water; concentration not reported	2000 mg/kg bw; 3 female Sprague-Dawley rats via gavage	No mortality occurred from dosing; no clinical signs of toxicity; no treatment-related effects at necropsy	> 2000 mg/kg bw	11
20% Calcium Silicate in feed	10,000 mg/kg bw; 10 male and 10 female Wistar rats via diet	No mortality occurred from dosing; no significant clinical findings; no treatment-related effects at necropsy	> 10,000 mg/kg bw	12
Hydrated Silica; suspended (12.1% (w/v)) in 0.85% saline	Male rats; no further details	No clinical signs of toxicity; no treatment-related effects at necropsy	> 5000 mg/kg	14,15

Table 6.. Acute toxicity studies

Ingredient/Concentration/Vehicle	Dose/Study Protocol	Results	LD₅₀ or LC₅₀	Reference
Hydrated Silica; 26% in water; pH 4.5	10 male Sprague-Dawley rats; no further details	Details not provided	40,000 mg/kg bw	^{14,15}
Hydrated Silica; suspended in water (33% w/w)	10,000, 12,600, 15,800, or 20,000 mg/kg bw; 5 Sprague-Dawley rats per sex per dose via gavage	No clinical signs of toxicity; stools were white for 2 days	> 20,000 mg/kg bw	^{14,15}
Hydrated Silica; in water	5620 mg/kg; 30 male Sprague-Dawley rats via single gavage dose	No clinical signs of toxicity; stools were white for 2 days	> 5620 mg/kg bw	^{14,15}
Hydrated Silica; in water	10,000 mg/kg bw; 5 male and 5 female Sprague-Dawley rats; no further details	Details not provided	> 10,000 mg/kg bw	¹⁵
Hydrated Silica; in water	31,600 mg/kg bw; 5 male and 5 female Sprague-Dawley rats; 24 h observation; no further details	Details not provided	> 31,600 mg/kg bw	¹⁵
Hydrated Silica; in 0.85% saline	10 to 5000 mg/kg bw; male rats; no further details	Distended stomachs with bloody patches at the pyloric end were observed at necropsy in animals that received > 100 mg/kg; at 5000 mg/kg, vascular stomach and reddened intestinal lining were observed	470 mg/kg	^{14,15}
Hydrated Silica; in saline	5000 mg/kg bw; male Sprague-Dawley rats; no further details	Details not provided	>5000 mg/kg bw	¹⁵
Hydrated Silica; average particle size 100 µm; in aqueous suspension of 1% carboxymethylcellulose	2000 or 5000 mg/kg bw; 10 male and 10 female Sprague-Dawley rats per single dose via gavage	No clinical signs of toxicity; no treatment-related effects at necropsy	> 5000 mg/kg	^{14,15}
Hydrated Silica; average particle size 8 µm; in carboxymethylcellulose	5110 mg/kg; 5 male and 5 female Wistar rats via gavage	No clinical signs of toxicity; no treatment-related effects at necropsy	> 5110 mg/kg	^{14,15}
Hydrated Silica; in olive oil	4000, 5040, or 6350 mg/kg bw; 5 male and 5 female Sprague-Dawley rats per dose group; no further details	Details not provided	> 6350 mg/kg bw	¹⁵
Hydrated Silica; in olive oil	5040, 6350, or 7900 mg/kg bw; 5 male and 5 female Sprague-Dawley rats per dose group; no further details	Details not provided	> 7900 mg/kg bw	¹⁵
Hydrated Silica; in 1% aqueous gum arabic solution	20,000, 25,200, or 31,800 mg/kg bw; 5 male and 5 female Sprague-Dawley rats per dose group; no further details	Details not provided	> 31,800 mg/kg bw	¹⁵
Hydrated Silica; in dispersion of 10% gum arabic in water	5000 mg/kg; 5 male and 5 female rats; no further details	No clinical signs of toxicity; no treatment-related effects at necropsy	> 5000 mg/kg	^{14,15}
Hydrated Silica; 30% neutralized with HCl	Male rats; no further details	Details not provided	10,000 mg/kg bw	^{14,15}
Potassium Silicate; undiluted; no further details reported	5000 mg/kg bw in 3 female Sprague-Dawley rats via gavage	No deaths occurred following treatment; no clinical or gross macroscopic signs of toxicity observed	> 5000 mg/kg bw	⁸
Potassium Silicate; concentration and vehicle not reported	3300, 3960, 4750, 5700, or 6860 mg/kg bw; 5 male and 5 female Cpb; Wu Wistar rats per dose; method of delivery not reported	Deaths per dose = 1/10 at 2.50 ml/kg, 2/10 at 3.00 ml/kg, 2/10 at 3.60 ml/kg, 3/10 at 4.32 ml/kg, and 10/10 at 5.20 ml/kg; sedation, signs of abdominal discomfort, sluggishness and unconsciousness were all reversible; no treatment-related effects at necropsy	5700 mg/kg bw	¹³
Silica (hydrophilic); in corn oil	178, 316, 562, 1000, 1780, or 3160 mg/kg bw; groups of 10 male Swiss mice; via gavage	No adverse signs of toxicity and no macroscopic lesions at necropsy	> 3160 mg/kg bw	^{14,15}
Silica; no further details	1000, 2150, or 3160 mg/kg bw in 5 male albino rats; no further details	No gross signs of systemic toxicity and no mortalities	> 3160 mg/kg bw	⁵⁰
Silica; no further details	30 male rats; no further details	No clinical signs of toxicity or mortalities during the 2 week observation period	> 5620 mg/kg bw	⁵¹
Silica; incorporated into a stock diet at a ratio of 1:4 (w/w)	10 Wistar male/female rats; dosing period was 24 h; no further details	No clinical signs of toxicity; no treatment-related effects at necropsy; stool grey in color with normal consistently but larger in size than normal	> 10,000 mg/kg	^{14,15}
Silica (hydrophilic); in water	5 male and 5 female Sprague-Dawley rats; no further details	Details not provided	> 5000 mg/kg bw	¹⁵
Silica (hydrophobic); in distilled water	1000, 1590, 2510, 3980, 6310, or 10,000 mg/kg bw; groups of 5 male and 5 female Sprague-Dawley rats; no further details	Details not provided	9200 mg/kg bw males >10,000 mg/kg bw females	¹⁵

Table 6.. Acute toxicity studies

Ingredient/Concentration/Vehicle	Dose/Study Protocol	Results	LD ₅₀ or LC ₅₀	Reference
Silica (hydrophobic); in corn oil	178, 316, 562, 1000, 1780, or 3160 mg/kg bw; groups of 10 male Sprague Dawley rats; no further details	Details not provided	> 3160 mg/kg bw	¹⁵
Silica (hydrophobic); in corn oil	5000 mg/kg bw; 5 male and 5 female Sprague-Dawley rats; no further details	Details not provided	> 5000 mg/kg bw	¹⁵
Silica (hydrophobic); in peanut oil	2500 or 5000 mg/kg bw; 10 male and 10 female Sprague-Dawley rats; no further details	Details not provided	> 5000 mg/kg	¹⁵
Silica; in olive oil	5040, 6350, or 7900 mg/kg in olive oil or 2500 or 5000 mg/kg in peanut oil	No clinical signs of toxicity or unscheduled mortalities during the 4 week observation period; no treatment-related effects at necropsy	> 7900 mg/kg in olive oil	²⁵
Silica; in aqueous suspension of 1% methylhydroxyethyl cellulose	2000 or 3300 mg/kg bw in 10 male and 10 female Sprague-Dawley rats per single dose via gavage	No clinical signs or gross macroscopic signs of toxicity observed	> 3300 mg/kg	^{14,15}
Silica (hydrophilic); in 0.5% methylcellulose	1000, 2750, or 3160 mg/kg bw; 5 male Boltzman rats per dose group; no further details	Details not provided	> 3160 mg/kg	¹⁵
Silica (hydrophobic); in polyethylene glycol 400	2000 mg/kg bw; 5 male and 5 female Wistar rats; no further details	Details not provided	> 2000 mg/kg bw	¹⁵
Sodium Magnesium Aluminum Silicate in water; no further details reported	2000 mg/kg bw in 6 female Sprague-Dawley rats via gavage	No deaths occurred following treatment; no clinical or gross macroscopic signs of toxicity observed	> 2000 mg/kg bw	⁷
Sodium Silicate; molar ratio = 3.35; no additional details provided	Male mice; no additional details provided	No details provided	6600 mg/kg bw	¹⁰
Sodium Silicate; molar ratio 3.27; concentration and vehicle not reported	3430, 4110, 4930, 5890, 7120, or 8490 mg/kg bw; 5 male and female Cpb:Wu Wistar rats per dose via gavage	Deaths per dose = 0/10 at 3430 mg/kg, 2/10 at 4110 mg/kg, 9/10 at 4930, 5890, and 7120 mg/kg, and 10/10 at 8490 mg/kg; sedation, signs of abdominal discomfort, sluggishness and unconsciousness; no treatment-related effects at necropsy	5150 mg/kg bw	¹⁰
Sodium Silicate; molar ratio = 3.3; no additional details provided	Rats; no additional details provided	No details provided	> 2000 mg/kg bw	¹⁰
Sodium Silicate in water; molar ratio = 3.38	Male Wistar rats; no additional details provided	Breathing difficulties, staggering gait, reduced motility; additional effects not reported	8650 mg/kg bw	¹⁰
Inhalation				
Hydrated Silica (5% SiO ₂); as mist; no further details	760 mg/m ³ ; male albino rats; 3.25 h whole body exposure; no further details	No deaths; no further details	> 760 mg/m ³	¹⁵
Hydrated Silica (20% SiO ₂); as mist; no further details	2240 or 2500 mg/m ³ ; male albino rats; 4.2 h whole body exposure; no further details	No deaths; no further details	> 2500 mg/m ³	¹⁵
Hydrated Silica (30% SiO ₂); as mist; no further details	520 or 560 mg/m ³ ; 2 male rats; 2.5 or 6 h nose-only exposure; preliminary test; no further details	No deaths; no further details	> 560 mg/m ³	¹⁵
Hydrated Silica (30% SiO ₂); as mist; no further details	3300 mg/m ³ ; male albino rats; 1.5 h whole body exposure; no further details	No deaths; no further details	> 3300 mg/m ³	¹⁵
Hydrated Silica; 45% of particles < 5 µm; surface area (SA) = 190	691 mg/m ³ ; 5 male and 5 female Wistar rats; 4 h whole body exposure; no further details	Some decreased body weight gain in females 2 days post-exposure which resolved by day 14; no abnormalities observed at necropsy	> 691 mg/m ³	^{14,15}
Hydrated Silica; no further details	2200 mg/m ³ ; 10 male Sprague-Dawley rats; 1 h nose-only exposure; no further details	One rat died 2 h after exposure; irritation and dyspnea observed in most animals; no further details	> 2200 mg/m ³	^{14,15}
Hydrated Silica; no further details	3100 mg/m ³ ; 2 male rats; 4 h nose-only exposure; no further details	Details not provided	> 3100 mg/m ³	¹⁵
30% Potassium Silicate solution in water; molar ratio 2.47; particle size distribution = 4% at 9 µm, 8.3% at 5.8 µm, 11.1% at 4.7 µm, 12% at 3.3 µm, 32% at 2.1 µm, 2.6% at 1.1 µm, 7.4% at 0.7 µm, and 2.6% at 0.4 µm)	2060 mg/m ³ ; whole body exposure for 4.4 h to 5 male and 5 female Sprague-Dawley rats	Animals had hunched posture and hypoactivity during exposure that reversed; no deaths or adverse effects during observation period or necropsy	> 2060 mg/m ³	⁸

Table 6.. Acute toxicity studies

Ingredient/Concentration/Vehicle	Dose/Study Protocol	Results	LD₅₀ or LC₅₀	Reference
Silica (hydrophobic); no further details	250 mg/m ³ ; groups of 10 male Swiss mice; 6 h whole body exposure; no further details	Clinical signs of toxicity included preening and occasional prostration; no significant findings at necropsy	> 250 mg/m ³	¹⁵
Silica (hydrophobic); particle size < 0.1 µm; SA = 300 m ² /g	90, 350, or 5000 mg/m ³ ; groups of 5 male and 5 females Sprague-Dawley rats; 4 h whole body exposure; no further details	Details not provided	90 mg/m ³	¹⁵
Silica (hydrophobic); particle size = 0.15 µm; SA = 130 m ² /g	2280 mg/m ³ ; 5 male and 5 female rats; 1 h whole body exposure; no further details	Details not provided	> 2280 mg/m ³	¹⁵
Silica (hydrophobic); particle size < 0.2 µm; SA = 130 m ² /g	350, 770, 2530, or 5300 mg/m ³ ; groups of 5 male and 5 females Sprague-Dawley rats; 4 h whole body exposure; no further details	All rats in 2530 and 5300 mg/m ³ dose groups died; severe red discoloration of the lungs was noted in the rats that died during the study; no further details	1650 mg/m ³	¹⁵
Silica (hydrophobic); particle size = 0.36 µm; SA = 200 m ² /g	0 or 4900 mg/m ³ ; groups of 5 male and 5 female Sprague-Dawley rats; 4 h whole body exposure; no further details	All animals of the test group died	< 4900 mg/m ³	¹⁵
Silica (hydrophobic); particle size < 0.4µm; SA = 300 m ² /g	80, 340, 1200, or 5000 mg/m ³ ; groups of 5 male and 5 females Sprague-Dawley rats; 4 h whole body exposure; no further details	Details not provided	800 mg/m ³	¹⁵
Silica (hydrophobic); particle size = 0.48 µm; SA = 200 m ² /g	0, 1260, 2830, or 6280 mg/m ³ ; groups of 5 male and 5 female Sprague-Dawley rats; 1 h whole body exposure; no further details	Details not provided	1260-2830 mg/m ³ ; no further details	¹⁵
Silica (hydrophobic); particle size = 0.54 µm; SA = 200 m ² /g	0 or 2190 mg/m ³ ; groups of 5 male and 5 female Sprague-Dawley rats; 4 h whole body exposure; no further details	All animals of the test group died	< 2190 mg/m ³	¹⁵
Silica (hydrophilic); particle size = 0.76 µm; SA = 200 m ² /g	2080 mg/ m ³ ; 5 male and 5 female Sprague-Dawley rats; 4 h nose-only exposure; no further details	Details not provided	> 2080 mg/m ³	^{14,15}
Silica (hydrophobic); particle size = 0.95-2.15 µm; SA = 300 m ² /g	90 or 840 mg/m ³ ; groups of 5 male and 5 female Wistar rats; 4 h whole body exposure; no further details	Results similar as those listed below; no further details	90-840 mg/m ³	¹⁵
Silica (hydrophobic); particle size = 1.175-1.275 µm; SA = 130 m ² /g	210, 540, or 2100 mg/m ³ ; groups of 5 male and 5 female Wistar rats; 4 h whole body exposure; no further details	All animals died in high dose group within 2.5 h of exposure; necropsy of this group discovered eye opacity, lung enlargement with red areas, and white material in the nasal turbinates; in the mid-dose group, 7/10 animals died during exposure; necropsy of mid-dose group discovered opaque eyes, dark enlarged lungs with red areas, white material in nasal turbinates, and red areas in the intestines; all rats in low-dose group survived; at necropsy, low- dose group had dark lungs with white and red areas	540 mg/m ³	¹⁵
Silica (hydrophobic); particle size = 1.4-1.8 µm; SA = 80 m ² /g	1094, 2863, 3730, or 5382 mg/ m ³ ; groups of 5 male and 5 female Wistar rats; 4 h whole body exposure; no further details	Details not provided	2863-3730 mg/m ³ ; no further details	¹⁵
Silica (hydrophobic); particle size =1-5 µm (83%) and 5-100 µm (17%); SA = 300 m ² /g	120, 400, 1370, or 3360 mg/m ³ ; groups of 3 male and 3 females Sprague-Dawley rats; 4 h whole body exposure; no further details	Details not provided	660 mg/m ³	¹⁵
Silica; particle size ≤ 3 µm (84%); no further details	10 Sprague-Dawley rats; 4 h whole body exposure; no further details	Clinical signs included nasal discharge during exposure and crusty eyes and nose and alopecia during the 14 d observation period; reduced body weight gain observed in females in the first 3 days post-exposure and then returned to normal; discolored lungs observed in 1 rat at necropsy	> 2.08 mg/m ³	¹⁴

Table 6.. Acute toxicity studies

Ingredient/Concentration/Vehicle	Dose/Study Protocol	Results	LD₅₀ or LC₅₀	Reference
Silica (hydrophilic); 56% of particles < 5 µm; SA = 200 m ² /g	139 mg/m ³ ; 5 male and 5 female Wistar rats; 4 h nose-only exposure; no further details	No clinical signs of toxicity and no organ abnormalities at necropsy	> 139 mg/m ³	^{14,15}
Silica (hydrophobic); particle size < 5 µm (56%) and ≥ 7.7 µm (44%); SA = 200 m ² /g	477 mg/m ³ ; 5 male and 5 female Wistar rats; 4 h whole body exposure; rats were observed for 14 days post-exposure and periodically weighed; no further details	No mortalities during exposure or observation period; body weights decreased during the first 2 days after exposure before returned to normal; necropsies were unremarkable	> 477 mg/m ³	²⁵
Silica (hydrophobic); particle size = 6.3-7.7µm; SA = 300 m ² /g	400, 700, or 2000 mg/m ³ ; groups of 5 male and 5 females Sprague-Dawley rats; 4 h nose-only exposure; no further details	Details not provided	600 mg/m ³	¹⁵
Silica (hydrophobic); particle size = 7.0-7.1µm; SA = 300 m ² /g	400 or 600 mg/m ³ ; groups of 5 male and 5 females Sprague-Dawley rats; 4 h nose-only exposure; no further details	Details not provided	500 mg/m ³	¹⁵
Silica (hydrophobic); particle size = 7.2-7.7µm; SA = 130 m ² /g	900 or 2200 mg/m ³ ; groups of 5 male and 5 females Sprague-Dawley rats; 4 h nose-only exposure; no further details	4/10 rats in high dose group died; severe discoloration of the lungs was noted in the rats that died during the study; surviving rats had normal lungs except 1 male and 2 females with trace discoloration	> 2200 mg/m ³	¹⁵
Silica (hydrophilic); SA = 200 m ² /g	0 or 191,300 mg/m ³ ; albino rats; 1 h nose-only exposure; no further details	Details not provided	> 191,300 mg/m ³	¹⁵
Silica (hydrophilic); SA = 380 m ² /g	0 or 207,000 mg/m ³ ; 10 male albino rats per dose group; 1 h nose-only exposure; no further details	Vigorous cleansing activity, hypoactivity, abdominal respiration, gasping, nasal exudation, closed eyes, crust-like material around nose and mouth, and chalky fur up to 2 days post-exposure	> 207,000 mg/m ³	¹⁵
Silica (hydrophobic); no further details	250 mg/m ³ ; groups of 10 male Wistar rats; 6 h whole body exposure; no further details	Clinical signs of toxicity included preening, hunching and occasional prostration; no significant findings at necropsy	> 250 mg/m ³	¹⁵
Silica (hydrophobic); no further details	670, 690, 710, 1540, or 3150 mg/m ³ ; 10 male albino rats per group; 1 h exposure; no further details	Details not provided	> 3150 mg/m ³	¹⁵
Silica (hydrophobic); no further details	250 mg/m ³ ; groups of 10 male English short hair guinea pigs; 6 h whole body exposure; no further details	Clinical signs of toxicity included preening; consolidation observed in the lungs of 2/9 animals; no significant findings at necropsy	> 250 mg/m ³	¹⁵

Table 7. Repeated dose toxicity studies

Ingredient/Concentration/ Dose/Vehicle	Species/Strain/Cell	Method	Results	Reference
<i>Dermal Toxicity</i>				
Silica; 0, 5, or 10 g/kg/d	2 male and 2 female albino rabbits per dose group; no further details	Test material applied for 18 h/g, 5 d/week for 3 weeks on intact and abraded skin; no further details	No signs of systemic toxicity and no gross or microscopic pathological findings; Silica content of blood, urine, spleen, liver, and kidney similar to controls	15
<i>Oral Toxicity</i>				
Hydrated Silica; 38.45, 79.78, or 160 g/male and 37.02, 72.46, or 157.59 g/female (1.25%, 2.5%, or 5%); in feed	Groups of 40 male and 40 female B ₆ C ₃ F ₁ mice	93-week dietary study	No remarkable findings with regards to hematology or organ weights; no differences between treated groups and controls with mortality; feed consumption was increased in mid- and high-dose groups while weight increases in males weeks 15-50 and in females weeks 30-50 were reduced	54
Hydrated Silica; 7500 mg/kg/d; in feed	6 albino male rats; no further details	Dietary study where rats received test material in feed 5 times per week for 2 weeks	All animals lost weight during treatment, but gained over the weekend and during post-observation period; no significant effects on the organs	14,15
Hydrated Silica; 16.5 g/kg/d (10% w/w) in group 1 and 5.8 g/kg/d (5% w/w) and 24.2 g/kg/d (20% w/w) in group 2; in feed	Two groups of 5 male and 5 female Sprague-Dawley rats	14-day dietary study; group1 received 16.5 g/kg/d test material for 14 days and group2 received 5.8 g/kg/d for days 1-10 and 24.2 g/kg/d for days 11-14; pathological exam not performed	NOAEL ≥ 24.2 g/kg/d; no clinical signs of toxicity or significant changes in feed/water consumption, body weight gains, or behavior	14,15
Hydrated Silica; average particle size = 15 µm; 1500 mg/kg/d; in aqueous solution	Female inbred rat; no further details	Daily gavage for 1 month	No clinical signs of toxicity or significant changes in feed consumption, body weight gain, or behavior; Silica content in liver = 1.5 µg, in kidney = 6.4 µg, and in spleen = 5.3 µg	14,15
Hydrated Silica; 0, 250, 1000, or 4000 mg/kg/d (0%, 0.5%, 2%, or 8%); in feed	Groups of 10 male and 10 female Wistar rats	13-week dietary study	NOEL = 4000 mg/kg/d; high dose group had increased feed intake associated with a decreased feed efficiency; increased mean absolute and relative weight for the cecum in the high dose group; no gross or microscopic pathological changes in any dose group	15
Hydrated Silica; 0, 2170, or 7950 mg/kg/d in males or 0, 2420, or 8980 mg/kg/d in females (0%, 3.2%, or 10%); in feed	Groups of 12 male and 12 female CD-1 rats	6-month dietary study	NOAEL = 8980 mg/kg/d; no clinical signs of toxicity or significant changes in feed consumption, growth, hematology, clinical chemistry, or gross or microscopic pathology	14,15
Hydrated Silica; 143.46, 179.55, or 581.18 g/male and 107.25, 205.02, or 435.33 g/female (1.25%, 2.5%, or 5%); in feed	Groups of 40 male and 40 female Fischer 344 rats	103-week dietary study	No differences between treated groups and controls with body weight, feed intake, behavior, or hematological or chemistry parameters; liver weights in females in the mid- and high-dose groups were lower at 12 to 24 months; no significant histopathological findings	54
Silica; 0.2%, 1.0%, or 2.5% in feed	Groups of 10 male rats; no further details	Dietary study 28 days in length; no further details	No adverse effects or unscheduled mortalities; gross necropsy findings unremarkable	51
Silica; 0.8 g/kg/d in feed; no further details	15 male and 15 female CD rats	Dietary study 4 weeks in length; no further details	No treatment-related effects observed	53
Silica; 0, 500, 1000, or 2000 mg/kg/d with a 2-week stepwise increase to 16,000 mg/kg/d (approximately 25% feed intake)	Groups of 5 male and 5 female Wistar rats	Dietary study 5 weeks in length for low- and mid-dose groups and 8 weeks for high-dose group	LOEL = 1000 mg/kg/d; NOEL = 500 mg/kg/d; high dose group had significant reduction in body weight associated with decreased feed intake; no significant changes in biological parameters or macroscopic findings; at microscopic examination, liver had severe atrophy in the epithelium	25
Silica (hydrophilic); 0, 700, 2100, or 3500 mg/kg/d (0%, 1%, 3%, or 5%); in feed	Groups of 15 male and 15 female Charles River rats	13-week dietary study; interim necropsies of 3 males and 3 females performed after 45 d	NOAEL = 3500 mg/kg/d; no clinical signs of toxicity or significant changes in feed consumption or growth rate; no gross or microscopic pathological changes; no increase in Silica content in the liver, kidney, spleen, blood, or urine after 45 or 90 d in the high dose group	14,15
Silica (hydrophobic); 0, 1000, 2000, or 4000 mg/kg/d (0%, 1%, 2%, or 4%); in feed	Groups of 10 male and 10 female Charles River rats	13-week dietary study	No clinical signs of toxicity; no gross or microscopic pathological changes; no changes in behavior or growth; a minimal change in the thyroid gland morphology was observed in the mid- and high-dose males	15
Silica; 3.2% or 10%; in feed	12 male and 12 female rats; no further details provided	6-month dietary study; no further details provided	No mortalities; only clinical sign as discolored stools; no remarkable findings with growth and development, feed consumption, histology, hematology, or at necropsy	51

Table 7. Repeated dose toxicity studies

Ingredient/Concentration/ Dose/Vehicle	Species/Strain/Cell	Method	Results	Reference
Silica; 0.78 or 3.00 g/week males and 0.55 or 2.11 g/week females; in feed	12 male and 12 female rats; no further details provided	6-month dietary study; no further details provided	Increase in the number of leukocytes in high dose females and of eosinophils in high dose males; dose-dependent decrease in glucose concentration and AP activity in male rats ; dose-dependent decrease in serum calcium concentration; reduced liver and prostate weights; no effects on body weight gain, feed consumption, blood chemistry, or urinalysis	51
Silica; 500 mg/kg/d	20 male and 20 female Wistar rats	6-month gavage study; 5 times/week	No clinical signs of toxicity and no macroscopic findings	25
Silica; 0.8 g/kg/d in feed; no further details	Male and female Beagle dogs; no further details	Dietary study 4 weeks in length; no further details	No treatment-related effects observed	53
<i>Inhalation Toxicity</i>				
Hydrated Silica; no further details	10 or 100 mg/m ³ ; 24 male CD rats; 6 h/d for 3 days followed by recovery periods of 1, 8, 30 or 90 days	Transient inflammatory tissue reaction observed in low dose group at 24 h post-exposure that resolved within 8 days; recovery in high dose group similar to that in low dose group	Not reported	52
Hydrated Silica (precipitated and gel) and Silica, aerosolized; particle sizes not provided; 1, 5, or 25 mg/m ³	10 male and 10 female Wistar (CrI:WI)WU BR rats per dose group	5-day study with 3-month recovery period; 6 h/d; nose-only exposure	No clinical signs of toxicity during exposure; silica levels in the tracheobronchial lymph nodes were below detection limits in all 3 groups; silica was found in the lungs at day 1 but had cleared by 3 months; all 3 test materials induced biomarkers of cytotoxicity in bronchoalveolar lavage (BAL) fluid, increases in lung and tracheobronchial lymph node weights, and histopathological lung changes in the high dose groups at day 1 post exposure; mid dose only induced histopathological changes and changes in BAL fluid; all effects except slight histopathological lung changes at the higher exposure levels reversed during the recovery period; low dose caused no adverse effects	18
Hydrated Silica, aerosolized; particle size not provided; 30 mg/m ³	45 male Fischer 344 rats	8-day study with a 112-day recovery; 6 h/d	Early and transient influx of cells into the lung tissue during exposure which returned to normal by day 12; BAL protein, lipid phosphorus, and saturated dipalmitoyl phosphatidyl-choline levels increased immediately after exposure but recovered day 5 post exposure; no differences between controls and treated lungs as to weight, DNA-, protein-, or hydroxyproline-content.	55,56
Hydrated Silica, aerosolized; particle size not provided; 0, 10.1, 50.5, and 154 mg/m ³ ; diluted 4:1 with deionized, distilled water	Male CD BR rats; no further details provided	4-week study with a 10- or 94-day recovery period; 6 h/d, 5 d/week	NOAEL=10.1 mg/m ³ ; dose-dependent increase in mean lung weight and lung to body weight ratio after 4 weeks of exposure in the mid and high dose groups; mean lung to body weight ratio continued to increase in the high dose group 10 days into recovery, but was similar to controls after 3 months; dust laden alveolar macrophages, neutrophilic infiltration, and Type II pneumocyte hyperplasia observed in the alveolar duct region of the lungs; pulmonary lesions progressively decreased in rats after the 10 day and 3 month recovery period; most dust-laden alveolar macrophages were cleared from the lungs 3 months post-exposure, but small numbers of minute silicotic nodule-like lesions were present in the alveolar ducts and perivascular regions where dust laden alveolar macrophages had aggregated; minimal collagen deposition observed in the silicotic nodule-like lesions but the lesions did not increase in size or number over time.; there was an increase in mean neutrophil count and globulin concentration and a decrease in mean lymphocyte count at the end of the treatment for the high dose group which were both still present after 3 months of recovery; tracheal and mediastinal lymph nodes were enlarged with nodular aggregates of dust-laden alveolar macrophages and hyperplastic reticulo-epithelial (RE) cells	57,58

Table 7. Repeated dose toxicity studies

Ingredient/Concentration/ Dose/Vehicle	Species/Strain/Cell	Method	Results	Reference
Hydrated Silica, aerosolized; particle size not provided; 0, 10, 50, or 150 mg/m ³	Groups of 25 male Crl:CD(SD)BR rats; no further details provided	4-week study with 10 day or 3-month recovery period; 6 h/d, 5 d/week	Dose-dependent lesions observed in the mid and high dose groups but not in low dose group; particles mostly phagocytized by alveolar macrophages in alveolar duct region and a few free particles were observed in Type I pneumonocytes in the alveoli; particle-laden alveolar macrophages directly penetrated into the bronchiolar interstitium from alveoli and accumulated in bronchus-associate lymphoid tissue, peribronchial, or perivascular interstitium and accumulated in the tracheobronchial lymph nodes; some particle-laden alveolar macrophages in the bronchus-associated lymphoid tissue transmigrated directly into bronchial lumen through the epithelium; migrated particle-laden alveoli macrophages observed to be necrotic and released particles in the tracheobronchial lymph nodes; at 3 months, lungs of the low dose group were normal while lungs of the mid dose group had a small number of tiny nodular aggregates of dust-laden alveoli macrophages and epithelioid cells were observed with one rat observed with a few silicotic nodules in perivascular regions adjacent to the bronchioles; high dose recovery group had decreased numbers of particle-laden alveoli macrophages that were sharply circumscribed in the alveoli; 3/10 rats had silicotic nodules in the perivascular region of the bronchioles	59
Hydrated Silica; particle and agglomerate/aggregate size 1 to ~120 µm; 35 mg/m ³	Male and female Wistar rats	13-week study with a 52-week recovery period; 6 h/d, 5 d/week	Slightly decreased body weight and increased lung and thymus weights were observed; necropsy revealed swollen and spotted lungs and enlarged mediastinal lymph nodes; microscopic examination revealed accumulation of alveolar macrophages, intra-alveolar leukocytes, and increased septal cellularity; accumulation of macrophages observed in the lymph nodes; collagen content in the lungs was slightly increased; effects of exposure mostly resolved within 26 weeks of recovery although accumulations of Silica and macrophages in the mediastinal lymph nodes were still present	60
Hydrated Silica (precipitated and gel) and Silica, aerosolized; particle size ≤4.7 µm; 0 or 15 mg/m ³	80 male Sprague Dawley rats	12-month study; 5.5 to 6 h/d, 5 d/week	LOAEL=6 to 9 mg/m ³ ; a few macrophage aggregates found in lungs; interstitial fibrosis associated with dense collections of mast cells was a trend in rats exposed to Silica, some incidences also occurred in some control animals; fibrosis was comparable between test and control groups	66
Hydrated Silica, aerosolized; particle size not provided; measurements ranges from 25 to 74 mg/ m ³	Groups of 35 Wistar rats; no further details provided	12-month study; 8 h/d, 5 d/week	Deaths occurred in 74% (26/35) and were treatment-related; majority of deaths from pulmonary vascular obstruction and emphysema from months 4-9; after 6 months, aggregations of focal pigmentation visible as reddish-tan foci of dust; greatly enlarged and firm lymph nodes were observed	64
Hydrated Silica, aerosolized; particle size not provided; 126 mg/m ³	84 rats; no further details provided	15-month study with up to 12-month recovery period; 8 h/d, 5 d/week	No treatment-related differences between test and control groups, most deaths were due to intercurrent infection; lung weights increased during exposure but returned to normal during recovery; particle phagocytosing macrophages accumulated in alveoli, bronchioles, and lymphoid tissue; hilar lymph nodes were mildly enlarged but disappeared at treatment termination; epithelial proliferation was minimal; mild deposition of reticulin fibers occurred in alveoli without collagen formation; no epithelization or pleural changes and no neoplasia; emphysematous effects may have been due to aging and recurrent epizootic pneumonia; silicotic processes were absent	65
Hydrated Silica (precipitated and gel) and Silica, aerosolized; particle size ≤4.7 µm; 0 or 15 mg/m ³	20 male Hartley guinea pigs	12-month study; 5.5 to 6 h/d, 5 d/week	Few macrophage containing particles of Silica were observed in the lungs and lymph nodes	66

Table 7. Repeated dose toxicity studies

Ingredient/Concentration/ Dose/Vehicle	Species/Strain/Cell	Method	Results	Reference
Hydrated Silica, aerosolized; particle size not provided; 0 or 126 mg/m ³	82 guinea pigs; no further details provided	24-month study; 8 h/d, 5 d/week; recovery period of up to 12 months	No treatment-related differences between test and control groups; lung weights increased during exposure but returned to normal during recovery; particle phagocytosing macrophages accumulated in alveoli, bronchioles, and lymphoid tissue; hilar lymph nodes were enlarged but disappeared at treatment termination; epithelial proliferation was minimal; mild deposition of reticulin fibers occurred in alveoli without collagen formation; no epithelization or pleural changes and no neoplasia; complete reversibility of Silica retention and inflammatory response with 6 months of recovery; silicotic processes were absent	65
Hydrated Silica, aerosolized; particle size not provided; 0 and 126 mg/m ³	50 rabbits; no further details provided	12-month study; 8 h/d, 5 d/week; recovery period of up to 12 months	No treatment-related differences between test and control groups; lung weights increased during exposure but returned to normal during recovery; particle phagocytosing macrophages accumulated in alveoli, bronchioles, and lymphoid tissue; hilar lymph nodes were enlarged but disappeared at treatment termination; epithelial proliferation was minimal; mild deposition of reticulin fibers occurred in alveoli without collagen formation; no epithelization or pleural changes and no neoplasia; silicotic processes were absent	65
Hydrated Silica, aerosolized; particle size not provided; 0, 28, 134, or 360 mg/m ³	10 New Zealand white rabbits; sex not reported	9-month study for mid- and high-dose groups; 27- month study for low-dose and control groups; 8 h/d, 5 d/week	LOAEL = 28 mg/ m ³ ; mid- and high-dose became distressed during exposure; fewer clinical signs that commenced later and receded more quickly were observed at lower concentrations: dyspnea and shortness of breath accompanied by cyanosis; elevated right and left ventricular pressures were concentration and time related; emphysema observed in high-dose group which decreased after treatment termination; pulmonary emphysema, vascular stenosis, alveolar cell infiltration, sclerosis, and epithelization granulomatosis, macrophage catarrh were observed; lesions were observed in liver, spleen and kidney; after 6 months of exposure, the cardiac pressure of the low dose group increased steadily; at 24 months, the elevation was 64% over pre-exposure pressure but effect was partially reversed with termination of treatment (34% after 12 months); the researcher reported concomitant radiographic changes, electrocardiographic deviations, modification of lung functions, hematolytic changes, anatomical cor pulmonale, congestive cardiac failure, emphysema, and chemical pneumonitis	63
Hydrated Silica (precipitated and gel) and Silica, aerosolized; particle size ≤4.7 µm; 0 or 15 mg/m ³	10 male <i>Macaca fascicularis</i> monkeys	13- or 18-month study; 6 h/d, 5 d/week	Decrease in lung respiratory volume and ventilatory mechanics more marked in the Silica group; dynamic pulmonary compliance, forced vital capacity, inspiratory capacity, total lung capacity, and forced expiratory flow were decreased; average flow resistance and closing volume were increased; lower lung volumes were observed in precipitated Hydrated Silica group; reductions in ventilatory performance and mechanical parameters, dynamic lung compliance, and forced expiratory flow in gel Hydrated Silica group; cytoplasmic changes in macrophages in the lungs and tracheal lymph nodes were observed; large numbers of macrophages and mononuclear cell aggregates were observed in the lungs; reticulin fibers were present in the aggregates in all 3 groups; in 6/10 monkeys exposed to Silica, collagen in varying quantities was found in 5 to 50% of the aggregates, with signs of early nodular fibrosis; in 3/10 monkeys no or little collagen was present; no or very few collagen fibers were observed in aggregates in the lung of Hydrated Silica groups; a review of this study noted that the monkeys may have been exposed to quartz or asbestos fibers during the course of the experiment	14,66

Table 7. Repeated dose toxicity studies

Ingredient/Concentration/ Dose/Vehicle	Species/Strain/Cell	Method	Results	Reference
Silica, aerosolized; no further details provided	15 Fischer 344 rats; no further details provided	8-day study with up to 120-day recovery period	Initial alveolar inflammation subsided by recovery day 12	56
Silica; particle sizes not provided; 0, 17, 44, or 164 mg/m ³	Groups of 40 male and 40 female Wistar rats; 6 male and 6 female rats served as unexposed controls	14-day study; 6 h/d, 5 d/week; whole body exposure chamber	Respiratory distress observed in all groups, and 1 female in the high dose group died; body weights and feed consumption were decreased in the males in the mid and high dose groups; hematological measurements were unremarkable; lung weights were increased in both sexes (47%, 65%, and 86% for the low, mid, and high dose groups, respectively) compared to controls; absolute and relative liver weights were decreased in males, but not females; dose-dependent changes observed in lungs (i.e., pale, spotted and/or spongy, occasionally irregular surface, alveolar interstitial pneumonia, early granulomata); mediastinal lymph nodes were enlarged	60
Silica; particle sizes not provided; 0, 46, 180, or 668 mg/m ³	Groups of 30 male and 30 female Wistar rats; 6 male and 6 female rats served as unexposed controls	14-day study; 6 h/d, 5 d/week; whole body exposure chamber	Respiratory distress was observed in all groups, and 1 male died in the high dose group; body weights were decreased in male mid and high dose groups and in high dose females; feed consumption was decreased in both sexes in the mid and high dose groups; lung weights were increased in both sexes compared to controls (males 25%, 39%, and 68%; females 34%, 50%, and 86% in the low, mid, and high dose groups, respectively); decreased liver weights observed in males of all dose groups and the high dose group females; lungs were spotted, swollen, and had irregular surfaces in the high dose groups as well as interstitial pneumonia and early granulomata; silica was observed in the mediastinal lymph nodes in the mid and high dose groups and 1 rat in the low dose group; an accumulation of alveolar macrophages and particulate material was observed in the lungs of males in the mid and high dose group	60
Silica; aerosolized; particle size 50-79 nm (nanoparticles); 0, 0.4 mg/m ³ , 1.4 mg/m ³ , or 5.4 mg/m ³	Groups of 15 male Sprague-Dawley rats	4- week study with up to 28 day recover; 6 h/d, 5 d/week; nose-only inhalation system	Minimal toxic effects included temporary decrease in body weight (high concentration group), increased levels of red blood cells (all concentration groups) and hemoglobin concentrations (low and middle concentration groups); no significant lung histopathological findings or adverse changes in inflammatory markers in bronchoalveolar lavage fluid; no significant toxicological or inflammatory changes in the lungs of the exposed groups during all recovery days	61

Table 7. Repeated dose toxicity studies

Ingredient/Concentration/ Dose/Vehicle	Species/Strain/Cell	Method	Results	Reference
Silica; particle size not provided; 1.3, 5.9, or 31 mg/m ³	Groups of 50 male and 50 female Wistar rats	13-week study with up to 39-week recovery; 6 h/d, 5 d/week; full body exposure	NOEL=1.3 mg/m ³ ; no mortalities during treatment or recovery; dose dependent increase in respiration rates; body weight gains were depressed; RBC count was increased in high dose males; white blood cells (WBC) were elevated in both males and females of mid and high dose groups but the concentration-response relationship was poor; blood cell counts returned to normal by week 39; necropsy revealed swollen and spotted lungs and enlarged mediastinal lymph nodes at 13 weeks with a dose-dependent severity; all groups had increased lung weights and collagen content, these effects were reduced to control levels by the end of recovery except for collagen content in males in the mid- and high-dose groups; in high-dose group post treatment, the average Silica amount in the lungs was 0.2 mg; no Silica above control levels could be detected in any rat at the end of recovery; microscopic evaluation after treatment revealed accumulation of alveolar macrophages and granular material, cellular debris, polymorphonuclear leukocytes, increased septal cellularity, alveolar bronchialization, focal interstitial fibrosis, cholesterol clefts, and granuloma-like lesions in the lung; no fibroblastic activity noted in lung lesions nor was there hyalinization; all pulmonary lesions types were more marked in males than in females; accumulation of macrophages was observed in the mediastinal lymph node at 13 and 26 weeks; focal necrosis and slight atrophy of the olfactory epithelium noted at week 13; interstitial fibrosis was not observed until 13 weeks post-exposure, with increasing incidence especially in the high-dose group, and a few in the mid-dose group	60
Silica, aerosolized; particle size not provided; 8 and 40 mg/m ³	Female Wistar rats; no further details provided	3-month study with a 7 day or 3-week recovery period; 1 h/d, 5 d/week	No macroscopic changes noted; dust cells noted in the lungs which decreased post-exposure; no fibrosis of the reticulo-cellular type and normal parenchyma of the lungs; decrease of Silica content in the lungs was observed 7 and 48 days after treatment termination with almost no Silica in the lungs after 3 months	14
Silica, aerosolized; mean diameter 0.81 µm; 0 or 50.4 ± 19 mg/m ³	4 male Fischer 344 rats; control group details not provided	13-week study with up to 8 months recovery period; 6 h/d, 5 d/week	Silica load increased quickly during the first 6.5 weeks of exposure (0.76 mg/lung) but less so after 13 weeks (0.88 mg/lung); Silica burden disappeared rapidly from lung tissue during recovery (15% after 12 weeks; 6% after 32 weeks); BAL showed mean cell numbers in the lavage increased 5- to 15-fold compared to control; cells comprised > 50% polymorphonuclear leukocytes (PMN) and some 2% lymphocytes whereas the control lavages only contained < 1% of either cell type; protein content and LDH and glucuronidase activities were markedly higher than controls; all BAL markers approached normal levels after 13 weeks recovery in most rats; invasion of neutrophils and macrophages into the alveoli noted after 6.5 weeks that decreased during recovery; fibrosis observed in alveolar septa which subsided during recovery; intensely stained TUNEL-positive cells were detected throughout the terminal bronchiolar epithelium and through the parenchyma of the lungs at exposure end	62

Table 7. Repeated dose toxicity studies

Ingredient/Concentration/ Dose/Vehicle	Species/Strain/Cell	Method	Results	Reference
Silica; particle size not provided; 25 to 85 mg/m ³	25 Wistar rats, half males and half females; control group had 42 rats; no further details provided	6-month study with 6-month recovery period; rats were exposed in inhalation chambers to aerated Silica for 8 h/d with passive exposure to settling dust the remaining 16 h; exposures were 5 d/week	LOAEL=53 mg/m ³ ; 44% rats died during exposure with most dying from pulmonary vascular obstruction and emphysema beginning at month 4; focal pigmentation was conspicuous after 3 months of exposure with profusely scattered small, dark-pink discrete but irregular subpleural foci of reaction; congestion of the lungs and lymph node enlargement observed after 3 months; an incipient tendency toward pulmonary emphysema observed after 4 months of exposure with lung distension and superficial alveoli dilation; atelectasis noted in some rats after 4 to 5 months; mononuclear macrophages forming clusters of plasma cells and lymphocytes observed in lung lymphatic system; alveolar space was infiltrated with large vacuolated cells; cytoplasm had a foamy appearance with macrophages fused to giant cells; progressive nodule formation in the lung parenchyma and peri- and paravascular, in some cases parabronchiolar distribution and accumulation, consisting of central macrophages and surrounding plasma cells, some nodules enveloped by an epithelial layer of cells; necrosis noted in the central zone of the nodules with tendency toward fibrosis in the nodules and evidence of progressive emphysematous processes around the nodules; average Silica load in the lung after 3 months was 1.5 mg/lung and reduced to 0.3 mg/lung at the end of recovery	64
Silica, hydrophobic and aerosolized; particle size not provided; 0, 10, 50, or 150 mg/m ³	Male rats; no further details provided	12-month study; 6 h/d, 5 d/week	No effects observed at lowest concentration; peribronchial lymph nodes enlargement and white foci on the lung surfaces and collections of foamy macrophages within the alveoli were observed in 50 and 150 mg/m ³ groups	15
Silica, aerosolized; 85% particles between 1 to 10 µm; 25 to 85 mg/m ³	Male and female albino guinea pigs, number per experiment described in Methods; 80 control animals	Up to 24 months; whole body exposure for 8 h/d with 16 h passive exposure to settling dust; study conducted as 3 experiments: Experiment 1: 40 animals exposed for 24 months, Experiment 2: 15 or 18 animals exposed for 12 or 24 months, respectively, with variable recovery periods up to 12 months, and Experiment 3: 17 animals exposed for 12 months with a 1-month recovery period and a re-exposure for 8 to 24 h	Focal pigmentation and lymph node enlargement after 1 month; lung emphysema after 4 to 8 months of exposure; atelectasis observed histologically with dominant response of bronchial and peribronchiolar intra-alveolar accumulations of giant cells; at 8 to 12 months there was incipient atrophy of infiltrated alveoli with compensatory expansion of adjacent alveoli; a combined effect of atelectasis and consolidation around bronchiole was noted with bronchioli distortion, along with incipient fibrosis around bronchioli and shrunken alveoli; a marked tendency toward cuboidal epithelization of atelectactic alveoli was noted by the end of the second year of exposure; medullary hyperplasia with the formation of slight amounts of reticulum was prominent during the second year of exposure in the lymphatic system with no inflammation, sinus catarrh, or fibrosis were noted in the lymph nodes; in the recovery phase after 12 months of exposure, a progressive recovery began almost immediately with no macroscopically visible anomalies after 1 year of recovery; residual sequelae of the tissue reactions were emphysema, mural fibrosis, and bronchiolar and bronchial ectasia stenosis	67
Silica, aerosolized; particles between 1 to 10 µm; 25 to 85 mg/m ³	10 New Zealand white rabbits; no further details provided	12-month study with a 6- and 12-month recovery period; 8 h/d	A progressive functional incapacitation and increased hematocrits observed in the majority of the rabbits, possibly due to the combined effect of pulmonary vascular obstruction and emphysema; Blood pressure changes (both increases and decreases) observed in the majority of the animals which partially recovered with discontinuation of treatment; essential pulmonary changes included peribronchiolar cellular catarrh, mural cellular infiltration along with deposition of reticulum and some collagen, the formation of peri-vascular cellular nodules, ductal stenosis, and emphysema; during recovery, the cellular reactions and emphysema regressed but minor focal alveolar mural collagen persisted.	68

Table 7. Repeated dose toxicity studies

Ingredient/Concentration/ Dose/Vehicle	Species/Strain/Cell	Method	Results	Reference
Silica, aerosolized; particle size not provided; 15 mg/m ³	5 <i>Macacus mulatta</i> monkeys with 15 untreated control monkeys; no further details provided	12-month study; a monkey was killed and necropsied at 3 and 6 months	Body weight gains decreased and activity decreased during the initial exposures; at 3 months, emphysema detectable with considerable cellular infiltration of the alveoli and alveolar septa associated with distention of alveoli or accumulation of exudate and macrophages; after 12 months, the lesions were marked pulmonary emphysema, alveolar wall sclerosis, vascular occlusions, and cor pulmonale, which was attributed to the emphysema and alveolar wall destruction; tracheobronchial lymph nodes were slightly enlarged but not fibrotic	⁶⁹
Silica, hydrophobic and aerosolized; particle size not provided; 0, 10, 50, or 100 mg/m ³	Male <i>Macaca fascicularis</i> monkeys	12-month study with a 2- or 24-month recovery; 6 h/d, 5 d/week	No effects observed at the lowest concentration; mid-and high groups had interstitial fibrosis, which did not resolve or progress during recovery; peribronchial lymph nodes were enlarged	¹⁵

Table 8. Genotoxicity studies

Ingredient/Concentration/Dose	Species/Strain/Cell	Method	Results	Reference
<i>In Vitro</i>				
Aluminum Silicate in water, up to 5017 µg/plate, with or without metabolic activation	<i>Salmonella typhimurium</i> strains TA97a, TA98, TA100, TA102, and TA1535	Ames test	Not genotoxic	11
Aluminum Silicate in DMSO; up to 250 µg/ml without metabolic activation; up to 500 µg/ml with metabolic activation	Chinese hamster ovary	HPRT gene mutation assay	Not genotoxic	11
Hydrated Silica; up to 10,000 µg/plate with and without metabolic activation	<i>S. typhimurium</i> strains TA 98, TA100, TA1535, TA 1537, and TA 1538	Ames test	Negative; not cytotoxic	14,15
Hydrated Silica; concentration not provided; without metabolic activation	<i>S. typhimurium</i> strain TA 1530, G-46	Ames test	Negative	14,15
Hydrated Silica; up to 10,000 µg/plate with and without metabolic activation	<i>Escherichia coli</i> WP2	Tryptophan reversion	Negative; not cytotoxic	14,15
Hydrated Silica; concentration not provided; without metabolic activation	<i>Saccharomyces cerevisiae</i> (D3)	Forward mutation	Negative	14,15
Hydrated Silica; 1-1000 µl/ml without metabolic activation	Human embryonic lung cells (Wi-38)	Chromosome aberration	No significant clastogenic activity	14,15
Silica; up to 10 M; details not reported	<i>Bacillus subtilis</i>	Rec assay	Negative	70
Silica; up to 10 M; details not reported	<i>E. coli</i> and <i>S. typhimurium</i> strains TA 98, TA 100, TA 1535, and TA 1538	Ames test	Not genotoxic	70
Silica (hydrophobic); 1580 µg/plate with and without metabolic activation	<i>S. typhimurium</i> strains TA 98, TA100, TA 1537	Ames test	Negative, not cytotoxic	14,15
Silica (hydrophilic); up to 5000 µg/plate with and without metabolic activation	<i>S. typhimurium</i> strains TA 98, TA 100, TA 1535, TA 1537, and TA 1538	Ames test (7 studies with identical test methods and findings)	Negative; not cytotoxic	14,15
Silica (hydrophilic); up to 10,000 µg/plate with metabolic activation	<i>S. typhimurium</i> strains TA 98, TA 100, TA 1535, TA 1537, and TA 1538	Ames test	Negative; not cytotoxic	14,15
Silica; up to 10,000 µg/plate in DMSO with and without metabolic activation	<i>E. coli</i> strain WP 2 and <i>S. typhimurium</i> strains TA98, TA100, TA1535, TA1537, TA1538	Ames test	Not genotoxic	71
Silica in a toluene extract; up to 1580 µg/plate with and without metabolic activation	<i>E. coli</i> strain WP2uvrA and <i>S. typhimurium</i> strains TA98, TA100, TA1535	Ames test; additional test performed with epoxide hydrolase inhibitor and glutathione depletor 1,1,1-trichloropropene-2,3-oxide was added to the activation mix in strain TA98 to increase sensitivity	Not genotoxic	25
Silica (hydrophobic); 5000 µg/plate with and without metabolic activation	<i>E. coli</i> WP2	Tryptophan reversion	Negative; not cytotoxic	14,15
Silica (hydrophobic); 5000 µg/plate with and without metabolic activation	<i>E. coli</i> WP2	Tryptophan reversion	Negative; not cytotoxic	14,15
Silica; up to 160 µg/cm ³	Chinese hamster lung fibroblasts	Micronucleus test	Weak, but significant, dose-dependent induction of micronuclei at cytotoxic concentrations; no clastogenicity observed in concentrations lower than cytotoxic levels	72
Silica; 19-300 µl/ml without metabolic activation and 250-1000 µl/ml with metabolic activation	Chinese hamster ovary (CHO) cells	Chromosomal aberration test	Negative	14
Silica (hydrophilic); 38-300 µl/ml without metabolic activation and 250-1000 µl/ml with metabolic activation	CHO cells	Chromosome aberration	No clastogenic activity	14,15
Silica; 10-250 µl/ml without metabolic activation and 100-500 µl/ml with metabolic activation	CHO cells	HGPRT assay	Negative	14

Table 8. Genotoxicity studies

Ingredient/Concentration/Dose	Species/Strain/Cell	Method	Results	Reference
Silica; 68.9 and 137.9 µg/cm ²	Chinese hamster fibroblasts (V79) and human embryonic lung fibroblasts (HEL 299)	Single-cell gel/Comet assay	Dose-dependent increase in DNA migration in the gel in both cell lines	⁷³
Silica; 0.3-1000 µl/ml; with and without metabolic activation	Primary rat hepatocytes	Unscheduled DNA synthesis	Negative; cytotoxic at 260-500 µl/ml	^{14,15}
Silica (hydrophilic); 10-250 µl/ml without metabolic activation and 100-500 µl/ml with metabolic activation	CHO cells	6-Thioguanine resistance	No significant mutagenic activity	^{14,15}
Silica (hydrophobic); 63-500 µl/ml with and without metabolic activation	CHO cells	Clastogenic activity; no further details provided	No clastogenic activity	^{14,15}
Silica (hydrophobic); 42-333 µl/ml with and without metabolic activation	CHO cells	Clastogenic activity; no further details provided	No clastogenic activity	^{14,15}
Sodium Metasilicate; up to 5000 µg/plate, with or without metabolic activation	<i>S. typhimurium</i> strains TA98, TA100, TA 1535, TA 1537 and <i>Escherichia coli</i> WP2	Ames test	Not genotoxic	⁹
Sodium Metasilicate; up to 675 µg/ml without metabolic activation and up to 1800 µg/ml with metabolic activation	Chinese hamster V79 cells	HGPRT gene mutation assay	Not genotoxic	⁹
36% Sodium Silicate; molar ratio = 3.3; up to 156.3 µg/ml with and without metabolic activation	Chinese hamster V79 cells	Chromosome aberration test	Not genotoxic	¹⁰
36% Sodium Silicate; molar ratio = 3.35; up to 675 µg/ml without metabolic activation and up to 1800 µg/ml with metabolic activation	Chinese hamster V79 cells	HGPRT gene mutation assay	Not genotoxic	¹⁰
Zinc Silicate; 100, 316, 1000, 3160 or 5000 µg/plate with or without metabolic activation	<i>S. typhimurium</i> strains TA98, TA100, TA102, TA1535, and TA1537	Ames test	Not genotoxic	⁶
<i>In Vivo</i>				
Hydrated Silica; 1.4-5000 mg/kg	Mice (host) + <i>S. typhimurium</i> TA 1530, G-46 (indicator)	Gene mutation (host mediated) method; a single or 5 intra-peritoneal (i.p.) injections of <i>S. typhimurium</i> ; cells collected 3 h after last administration	No mutagenic activity	¹⁵
Hydrated Silica; 1.4-5000 mg/kg	Mice (host) + <i>S. cerevisiae</i> D3 (indicator)	Mitotic recombination (host mediated); a single or 5 i.p. injections of <i>S. cerevisiae</i> ; cells collected 3 h after last administration	No genotoxic activity	¹⁵
Hydrated Silica; 1.4-5000 mg/kg	Male Sprague-Dawley rats	Chromosome aberration study with rat bone marrow; animals were killed at 6, 24, or 48 h after oral dosing	Negative	¹⁵
Hydrated Silica; 1.4-5000 mg/kg	Male Sprague-Dawley rats	Chromosome aberration study with rat bone marrow; animals were killed at 6 h after oral dosing	Negative	¹⁵
Hydrated Silica; 1.4-5000 mg/kg	8 mated female Sprague-Dawley rats	Dominant lethal mutation assay; animals were killed 14 days after mating for uterus examination; oral dosing	Negative	¹⁵
Hydrated Silica; 1.4-5000 mg/kg	8 mated female Sprague-Dawley rats	Dominant lethal mutation assay; animals were killed 14 days after mating for uterus examination; oral dosing	Negative	¹⁵

Table 9. Dermal irritation and sensitization

Ingredient/Concentration/ Dose/Vehicle	Test System	Method	Results	Reference
<i>Irritation – In Vitro</i>				
Aluminum Silicate; 25 mg in Dulbecco's phosphate buffered saline	EpiDerm™ tissue	EpiDerm™ human skin model; material applied for 30 min	Not irritating	11
Zinc Silicate; undiluted; 25 mg	EpiDerm™ tissue	EpiDerm™ reconstructed human epidermis model in accordance with OECD Test Guideline 439; test material applied to 0.63 cm ² test tissue for 60 min	Not irritating	6
<i>Irritation – Animal</i>				
Hydrated Silica; 500 mg as a 23% solution in methyl ethyl cellulose	12 rabbits; no further details	Dermal irritation study; test site occluded for 24 h; skin intact and abraded	No signs of irritation	15
Hydrated Silica; 20 mg	8 rabbits; no further details	Dermal irritation study; test site occluded for 24 h; skin intact and abraded	No signs of irritation	15
Hydrated Silica; 33 mg	6 rabbits; no further details	Dermal irritation study; test site occluded for 24 h; skin intact and abraded	Very slight erythema on 4 abraded sites and 5 intact sites at 24 h	15
Hydrated Silica; 190 mg	6 rabbits; no further details	Dermal irritation study; test site occluded for 24 h; skin intact and abraded	Very slight erythema on 3 abraded sites and 4 intact sites at 24 h	15
Hydrated Silica; 500 mg	3 rabbits; no further details	Dermal irritation study; test site occluded for 4 h; skin intact	No signs of irritation	15
Hydrated Silica; 500 mg	6 rabbits; no further details	Dermal irritation study; test site occluded for 24 h; skin intact	No signs of irritation	15
Hydrated Silica; 500 mg	12 rabbits; no further details	Dermal irritation study; test site occluded for 24 h; skin intact and abraded	No signs of irritation	15
Hydrated Silica; 500 mg as a 50% solution in olive oil	12 rabbits; no further details	Dermal irritation study; test site occluded for 24 h; skin intact and abraded	No signs of irritation	15
Hydrated Silica (hydrophobic); 500 mg as a 50% solution in olive oil	12 rabbits; no further details	Dermal irritation study; test site occluded for 24 h; skin intact and abraded	No signs of irritation	15
25% dilution of 29% (weight) Potassium Silicate; molar ratio = 3.9; 0.5 ml in deionized water	5 New Zealand White rabbits; sex not reported	Dermal irritation study in accordance with OECD Test Guideline 404; test material applied to shaved test site and occluded for 4 h before being rinsed; test site examined for up to 7 days	Not irritating; PDII = 0	8,13
25% dilution of 35% (weight) Potassium Silicate; molar ratio = 3.4; 0.5 ml in deionized water	3 New Zealand White rabbits; sex not reported	Dermal irritation study in accordance with OECD Test Guideline 404; test material applied to shaved test site and occluded for 4 h before being rinsed; test site examined for up to 7 days	Not irritating; very slight erythema 24 and 48 h after treatment; PDII = 0	8,13
29% (weight) Potassium Silicate; molar ratio = 3.9; 0.5 ml in deionized water	5 New Zealand White rabbits; sex not reported	Dermal irritation study in accordance with OECD Test Guideline 404; test material applied to shaved test site and occluded for 4 h before being rinsed; test site examined for up to 7 days	Not irritating; slight erythema cleared by 24 h; PDII = 0.25	8,13
33% (weight) Potassium Silicate; molar ratio = 3.0; 0.5ml in water	1 male New Zealand White rabbit	Dermal irritation study in accordance with OECD Test Guideline 404; test material applied to shaved test site and semi-occluded for 4 h before being rinsed off with water; test site examined for up to 5 days	Moderately irritating; well-defined erythema and very slight edema persisted for at least 5 days; PDII = 3	8,13
35% (weight) Potassium Silicate; molar ratio = 3.4; 0.5ml in deionized water	3 New Zealand White rabbits; sex not reported	Dermal irritation study in accordance with OECD Test Guideline 404; test material applied to shaved test site and occluded for 4 h before being rinsed; test site examined for up to 7 days	Not irritating; slight erythema after 1 h that cleared after 48 h; PDII = 0.17	8,13
36% (weight) Potassium Silicate; molar ratio = 2.0; 0.5ml in water	1 female New Zealand White rabbit	Dermal irritation study in accordance with OECD Test Guideline 404; test material applied to shaved test site and semi-occluded for 4 h before being rinsed off with water; test site examined for up to 5 days	Slightly irritating; transient erythema observed cleared by day 5; primary dermal irritation index (PDII) = 1	8,13
Silica (hydrophobic); 500 mg as a 6% solution in methyl ethyl cellulose	12 rabbits; no further details	Dermal irritation study; test site occluded for 24 h; skin intact and abraded	No signs of irritation	15
Silica (hydrophilic); 500 mg as a 12% solution in methyl ethyl cellulose	12 rabbits; no further details	Dermal irritation study; test site occluded for 24 h; skin intact and abraded	No signs of irritation	14,15
Silica (hydrophobic); 500 mg in 2 ml water	6 rabbits; no further details	Dermal irritation study; test site occluded for 24 h; skin intact and abraded	No signs of irritation	15

Table 9. Dermal irritation and sensitization

Ingredient/Concentration/ Dose/Vehicle	Test System	Method	Results	Reference
Silica (hydrophilic); 500 mg in 3 ml saline	6 rabbits; no further details	Dermal irritation study; test site occluded for 24 h; skin intact and abraded	No signs of irritation on intact skin; slight erythema on 3 abraded sites	15
Silica (hydrophilic); 500 mg moistened with saline	6 rabbits; no further details	Dermal irritation study; test site occluded for 24 h; skin intact and abraded	Very slight erythema on 1 intact site at 24 h; very slight to well-defined erythema on abraded sites; no sign of erythema at 72 h post-patch removal	15
Silica (hydrophobic); 500 mg	6 rabbits; no further details	Dermal irritation study; test site semi-occluded for 4 h; skin intact	No signs of irritation	15
Silica (hydrophobic); 500 mg moistened with polyethylene glycol	6 rabbits; no further details	Dermal irritation study; test site occluded for 24 h; skin intact and abraded	No signs of irritation	15
Silica (hydrophobic); silane treated; 500 mg moistened with corn oil	6 rabbits; no further details	Dermal irritation study; test site occluded for 24 h; skin intact and abraded	No signs of irritation	15
10% aq. Sodium Metasilicate; 0.5 ml in water	3 rabbits; strain and sex not reported	Dermal irritation study in accordance with OECD Test Guideline 404; test material applied to shaved test site and semi-occluded for 4 h before being rinsed; test site examined for up to 72 h	Slightly irritating; severity of erythema reduced but persisted through day 2; edema in 1 animal reversed by day 2; PDII = 1.22	9
50% aq. Sodium Metasilicate; 0.5 ml in water	3 rabbits; strain and sex not reported	Dermal irritation study in accordance with OECD Test Guideline 404; test material applied to shaved test site and semi-occluded for 4 h before being rinsed; test site examined for up to 72 h	Irritating; PDII = 3.67	9
57.5% (weight) Sodium Metasilicate (pentahydrate); 0.5 g	3 white landrace rabbits; sex not reported	Dermal irritation study in accordance with OECD Test Guideline 404; test material applied to shaved test site and semi-occluded for 4 h before being rinsed; test site examined for up to 14 days	Corrosive; 2/3 animals had acute skin necrosis and the 3 rd had pigmented necrosis; wounds persisted for more than 14 days; PDII = 7.8	9
83% (w/w) Sodium Metasilicate as aqueous paste; pH 12.4; 0.5 g/0.10 purified water; 0.3 ml applied	3 male New Zealand hybrid rabbits	Dermal irritation study in accordance with OECD Test Guideline 404; test material applied to shaved test site and semi-occluded for 4 h before being rinsed; test site examined for up to 14 days	Corrosive; erythema persisted for at least 14 days; edema observed 1 h post-treatment but cleared by 72 h; necrosis persisted 7-14+ days; PDII = 4.67	9
97% (weight) Sodium Metasilicate (anhydrous); 0.5 g	3 white landrace rabbits; sex not reported	Dermal irritation study in accordance with OECD Test Guideline 404; test material applied to shaved test site and semi-occluded for 4 h before being rinsed; test site examined for up to 14 days	Corrosive; 2/3 animals had acute skin necrosis with well-defined edema; wounds persisted for more than 14 days; third animal had wounds that were observed at up to 72 h but had healed by day 14; PDII = 5.1	9
Sodium Metasilicate (anhydrous); 0.5 g in water	1 male New Zealand White rabbits	Dermal irritation study in accordance with OECD Test Guideline 404; test material applied to shaved test site and semi-occluded for 4 h before being rinsed; test site examined for up to 5 days	Corrosive; necrosis observed; PDII = 8; no erythema or edema observed when applied as dry powder	9
Sodium Metasilicate (pentahydrate); 0.5 g in water	1 female New Zealand White rabbits	Dermal irritation study in accordance with OECD Test Guideline 404; test material applied to shaved test site and semi-occluded for 4 h before being rinsed; test site examined for up to 5 days	Corrosive; necrosis observed; PDII = 8; no erythema or edema observed when applied as dry powder	9
Sodium Metasilicate; concentration not reported; fine powder with pH of 12.4 tested undiluted; 0.5 g	3 New Zealand White rabbits; sex not reported	Dermal irritation study in accordance with OECD Test Guideline 404; test material applied to shaved test site and semi-occluded for 4 h before being rinsed; test site examined for up to 14 days	Not irritating; 1/3 animals had erythema and edema 1 h post-treatment that cleared by 72 h; PDII = 0.17	9
Sensitization – Animal				
0%, 5%, 10%, or 25% (w/v) Aluminum Silicate in dimethyl sulfoxide; application volume = 25 µl	4 female CBA/CaOlaHsd mice/dose group	Local lymph node assay (LLNA)	Not sensitizing; stimulation indices (SI) below 3	11
Hydrated Silica; 10% at induction, and 1%-20% at challenge; in distilled water	10 female Hartley albino guinea pigs treated; 5 guinea pigs control	Guinea pig maximization test	Not sensitizing	78

Table 9. Dermal irritation and sensitization

Ingredient/Concentration/ Dose/Vehicle	Test System	Method	Results	Reference
30% Potassium Silicate solution; molar ratio = 2.47	20 male Hartley guinea pigs received test material; 10 animals served as control	Buehler sensitization test; animals were induced with undiluted test material and challenged at 75%	Not sensitizing	8
0%, 10%, 25%, or 50% Zinc Silicate in acetone/olive oil (4:1; v/v)	6 female NMRI mice/dose group	LLNA	Not sensitizing; SI below 1.4; irritant response noted	6
Sensitization- Human				
17% Hydrated Silica in a facial mask (0.05 ml)	27 subjects (18 males, 9 females)	HRIPT; test sites pre-treated with 25% sodium lauryl sulfate (SLS; aq.; 0.05 ml) under occlusion for 24 h prior to induction; occluded	Not sensitizing	79
45% Hydrated Silica; no further details reported	20 subjects (10 males, 10 females)	HRIPT; details not reported	Not sensitizing	14
Hydrated Silica (micronized gel) in a dusting powder; concentration and dose not reported	300 patients	Dermal irritation and sensitization study; details not reported	Non-irritating and non-toxic; little or no sensitizing reactions observed	51
21.74% Silica in a facial powder in a 30% aq. solution	27 subjects (18 males, 9 females)	HRIPT; test sites pre-treated with 25% SLS aq. (0.05 ml) under occlusion for 24 h prior to induction; occluded	Not sensitizing	80

Table 10. Ocular irritation

Ingredient/Concentration/ Dose/Vehicle	Test System	Method	Results	Reference
In Vitro				
Aluminum Silicate tested pure; no vehicle; 164.3 mg	Lohmann Leghorn chicken eggs	HET-CAM method; treatment duration = 5 min	Not irritating	11
Sodium Metasilicate; concentration not reported; undiluted; 50 mg	New Zealand White rabbit eyes	In vitro rabbit eye study; treatment duration = 0.17 min; eyes studied for opacity for up to 4 h post-treatment	Corrosive	9
Zinc Silicate; 20% suspension in 750 µl of physiological saline solution (0.9% NaCl)	Bovine corneas	Bovine corneal opacity and permeability test (BCOP); exposure was 4 h	Irritating; mean opacity score of 3 corneas was 6.31; mean fluorescein retention/leakage score was < 0.01	6
Animal				
Hydrated Silica; 0.1 ml of 50% dilution in olive oil	8 male New Zealand white rabbits	Ocular irritation study; eyes rinsed after 5 min in 3 rabbits or not rinsed in 5 rabbits	No signs of irritation in rinsed eyes; very slight erythema observed up to 24 h after instillation	25
Hydrated Silica; 100 mg instilled; 0.2 ml of 50% slurry	6 rabbits; no further details	Ocular irritation study; no further details	No signs of irritation	15
Hydrated Silica; 9 mg instilled	9 rabbits; no further details	Ocular irritation study; eyes rinsed after 2 sec in 3 rabbits, 4 sec in 3 rabbits, or not rinsed in 3 rabbits	No signs of irritation	15
Hydrated Silica; 40 mg instilled	3 rabbits; no further details	Ocular irritation study; no further details	No signs of irritation	15
Hydrated Silica; 100 mg instilled	3 rabbits; no further details	Ocular irritation study; no further details	Slight redness at 24, 48, and 72 h that resolved by day 4; mean score = 0.7	15
Hydrated Silica; 100 mg instilled	8 rabbits; no further details	Ocular irritation study; eyes rinsed after 5 min in 3 rabbits or not rinsed in 5 rabbits	No signs of irritation	15
Hydrated Silica; 100 mg instilled	9 rabbits; no further details	Ocular irritation study; eyes rinsed after 4 sec in 3 rabbits or not rinsed in 6 rabbits	No signs of irritation	15
25% dilution of 29% (weight) Potassium Silicate; molar ratio = 3.9; 0.1 ml in deionized water	6 New Zealand White rabbits; sex not reported	Ocular irritation study in accordance with OECD Test Guideline 405; eyes not rinsed; observed for up to 7 days post- treatment	Not irritating	8,13
25% dilution of 35% (weight) Potassium Silicate; molar ratio = 3.4; 0.1 ml in water	3 New Zealand White rabbits; sex not reported	Ocular irritation study in accordance with OECD Test Guideline 405; eyes not rinsed; observed for up to 7 days post- treatment	Not irritating	8,13
29% (weight) Potassium Silicate; molar ratio = 3.9; 0.1 ml in water	6 New Zealand White rabbits; sex not reported	Ocular irritation study in accordance with OECD Test Guideline 405; eyes not rinsed; observed for up to 7 days post- treatment	Not irritating	8,13

Table 10. Ocular irritation

Ingredient/Concentration/ Dose/Vehicle	Test System	Method	Results	Reference
~30% Potassium Silicate in water; molar ratio = 2.47; 0.1 ml	3 New Zealand White rabbits; sex not reported	Ocular irritation study; eyes not rinsed; observed for up to 7 days post-treatment	Slightly irritating	8
35% (weight) Potassium Silicate; molar ratio = 3.4; 0.1 ml in water	3 New Zealand White rabbits; sex not reported	Ocular irritation study in accordance with OECD Test Guideline 405; eyes not rinsed; observed for up to 7 days post-treatment	Slightly irritating; redness and chemosis of the conjunctivae (scores 1.0-1.3 and 1.3-1.5, respectively) observed up to 7 days post-treatment	8,13
Silica; 0.1 ml of 50% dilution in olive oil	8 male New Zealand white rabbits	Ocular irritation study; eyes rinsed after 5 min in 3 rabbits or not rinsed in 5 rabbits	No irritation	25
Silica (hydrophilic); 3 mg instilled	3 rabbits; no further details	Ocular irritation study; no further details	Slight to mild erythema that resolved by 48 h	50
Silica (hydrophobic); 3 mg instilled	9 rabbits; no further details	Ocular irritation study; eyes not rinsed in 3 rabbits, eyes rinsed after 2 sec in 3 rabbits, or after 4 sec in 3 rabbits	Transient slight to moderate conjunctival erythema observed and 1 and 4 h post-treatment that resolved within 24 h	15
Silica (hydrophilic); 3.5 mg instilled	6 rabbits; no further details	Ocular irritation study; no further details	Slight conjunctival erythema or chemosis in some animals at 24, 48 and 72 h; mean score 0.6 and 0.1, respectively; transient corneal opacity observed in 2 animals at 4 h	15
Silica (hydrophobic); 6 mg instilled	9 rabbits; no further details	Ocular irritation study; eyes not rinsed in 3 rabbits, eyes rinsed after 2 sec in 3 rabbits, or eyes rinsed after 4 sec in 3 rabbits	No signs of irritation	15
Silica (hydrophilic); 9 mg instilled; neat and in aqueous suspension; no further details	Rabbits; no further details	Draize ocular irritation study; rinsed and unrinsed eyes; no further details	Neat material was a mild irritant in unrinsed eyes (score = 2.4); no irritation in rinsed eyes or those treated with aqueous suspension	51
Silica (hydrophobic); 10 mg instilled	9 rabbits; no further details	Ocular irritation study; eyes not rinsed in 6 rabbits; eyes rinsed after 30 s in 3 rabbits	No signs of irritation	15
Silica; 10 mg instilled; neat and in aqueous solution; no further details	Rabbits; no further details	Ocular irritation study; some eyes rinsed after 2 sec, 4 sec, or not rinsed; no further details	Faint irritation in mucous tissues in eyes treated with neat material and not rinsed; no irritation in eyes that were rinsed and with aqueous solution	51
Silica (hydrophobic); 10-20 mg instilled	9 rabbits; no further details	Ocular irritation study; eyes not rinsed in 6 rabbits; eyes rinsed after 30 sec in 3 rabbits	No signs of irritation in rinsed eyes; 2 unrinsed eyes had slight erythema for 24 h after instillation; mean score = 0.1 at 24, 48, and 72 h	15
Silica (hydrophobic); 25 mg instilled	9 rabbits; no further details	Ocular irritation study; eyes not rinsed in 6 rabbits; eyes rinsed after 30 sec in 3 rabbits	No signs of irritation in rinsed eyes; 2 unrinsed eyes had slight erythema for 24 h after instillation; mean score = 0.1 at 24, 48, and 72 h	15
Silica (hydrophobic); 100 mg instilled	8 rabbits; no further details	Ocular irritation study; eyes not rinsed in 5 rabbits; eyes rinsed after 5 min in 3 rabbits	No signs of irritation	15
Silica (hydrophobic); 100 mg instilled	9 rabbits; no further details	Ocular irritation study; eyes not rinsed in 6 rabbits; eyes rinsed after 4 sec in 3 rabbits	No signs of irritation	15
Silica (hydrophilic); 100 mg instilled	8 rabbits; no further details	Ocular irritation study; eyes not rinsed in 5 rabbits; eyes rinsed in 3 rabbits after 5 min	No signs of irritation	15
Silica (hydrophilic); 100 mg instilled	9 rabbits; no further details	Ocular irritation study; eyes not rinsed in 6 rabbits; eyes rinsed after 30 sec in 3 rabbits	No signs of irritation in rinsed eyes; mean score 0.15; very slight conjunctival erythema up to 48 h	15

REFERENCES

1. Andersen F, (ed),. Final Report on the Safety Assessment of Aluminum Silicate, Calcium Silicate, Magnesium Aluminum Silicate, Magnesium Silicate, Magnesium Trisilicate, Sodium Magnesium Silicate, Zirconium Silicate, Attapulgite, Bentonite, Fuller's Earth, Hectorite, Kaolin, Lithium Magnesium Silicate, Lithium Magnesium Sodium Silicate, Montmorillonite, Pyrophyllite, and Zeolite. *Int J Toxicol*. 2003;22(Suppl 1):37-102.
2. Andersen FA, (ed). Final Report on the Safety Assessment of Potassium Silicate, Sodium Metasilicate, and Sodium Silicate. *Int J Toxicol*. 2005;24(Suppl 1):103-117.
3. Becker L, Bergfeld W, Belsito D, et al. 2009. Safety Assessment of Silica and Related Cosmetic Ingredients. Review CI, ed.
4. Nikitakis J, Lange B. wINCI: International Cosmetic Ingredient Dictionary and Handbook. <http://webdictionary.personalcarecouncil.org/jsp/Home.jsp>. Washington, DC: Personal Care Products Council. Last Updated: 2018. Accessed: 4/5/2018.
5. Becker L, Bergfeld W, Belsito D, et al. Safety Assessment of Silylates and Surface-Modified Siloxysilicates. *Int J Toxicol*. 2013;32(Suppl 1):5S-24S.
6. European Chemicals Agency. Dizinc Orthosilicate. <http://echa.europa.eu/>. Last Updated: 3/23/2018. Accessed: 5/14/2018.
7. European Chemicals Agency. Silicic Acid, Aluminum Magnesium Sodium Salt. <https://echa.europa.eu>. Last Updated: 2/4/2018. Accessed: 5/16/2018.
8. European Chemicals Agency. Silicic Acid, Potassium Salt. <https://echa.europa.eu>. Last Updated: 4/13/2018. Accessed: 5/16/2018.
9. European Chemicals Agency. Disodium Metasilicate. <https://echa.europa.eu>. Last Updated: 5/18/2018. Accessed: 5/18/2018.
10. European Chemicals Agency. Silicic Acid, Sodium Salt. <https://echa.europa.eu>. Last Updated: 5/10/2018. Accessed: 5/18/2018.
11. European Chemicals Agency. Aluminatesilicate. <https://echa.europa.eu>. Last Updated: 5/10/2018. Accessed: 5/21/2018.
12. European Chemicals Agency. Silicic Acid, Calcium Salt. <https://echa.europa.eu>. Last Updated: 5/1/2018. Accessed: 5/21/2018.
13. OECD SIDS. Soluble Silicates. 2004. <http://www.inchem.org/documents/sids/sids/solublesilicates.pdf>. Accessed 5/16/2018.
14. OECD SIDS. Synthetic amorphous silica and silicates. Berlin, Germany 2004. <https://hpcchemicals.oecd.org/UI/handler.axd?id=4c05aa97-50de-4090-a1cb-70a5e8ed2c8d>. Pages 1-254.

15. European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC). Synthetic Amorphous Silica (CAS No. 7631-86-9). Brussels 2006. JACC No. 51. <http://www.ecetoc.org/wp-content/uploads/2014/08/JACC-051.pdf>. Pages 1-237.
16. Heppleston A. The fibrogenic action of silica. *Br Med Bull.* 1969;25(3):282-287.
17. The Synthetic Amorphous Silica and Silicates Industry Association. 2008. Nanoscale Materials Stewardship Program (NMSP) Voluntary Submittal Package for Synthetic Amorphous Silica. Washington, DC. (Submitted to CIR by the Synthetic Amorphous Silica and Silicate Industry Association on March 11, 2019.)
18. Arts J, Muijsers H, Duistermaat E, Junker K, Kuper C. Five-day inhalation toxicity study of three types of synthetic amorphous silicas in Wistar rats and post-exposure evaluations for up to 3 months. *Food Chem Toxicol.* 2007;45(10):1856-1867.
19. Pavlich D. 2019. Comments from the Synthetic Amorphous Silica and Silicate Industry Association to Cosmetic Ingredient Review. (Unpublished data submitted to CIR by the Synthetic Amorphous Silica and Silicate Industry Association on March 11, 2019.)
20. Council of Experts, United States Pharmacopeial Convention. *Food Chemicals Codex*. 8th ed. Rockville, MD: United States Pharmacopeia (USP); 2012.
21. Byers P, Gage J. The toxicity of precipitated silica. *Brit J Industr Med.* 1961;18(4):295-302.
22. Gray C, Muranko H. Studies of robustness of industrial aciniform aggregates and agglomerates - carbon black and amorphous silicas: A review amplified by new data. *JOEM.* 2006;48(12):1279-1290.
23. Yates D, Healy T. The structure of the silica/electrolyte interface. *J Colloid Interface Sci.* 1976;55(1):9-19.
24. Hurd A, Flower W. In situ growth and structure of fractal silica aggregates in a flame. *J Colloid Interface Sci.* 1988;122(1):178.
25. Lewinson J, Mayr W, Wagner H. Characterization and toxicological behavior of synthetic amorphous hydrophobic silica. *Regul Toxicol Pharmacol.* 1994;20(1 Pt 1):37-57.
26. Cabot Corporation. 2004. CAB-O-SIL® Fumed Silica in Cosmetic and Personal Care Products.
27. U.S. Food and Drug Administration Center for Food Safety & Applied Nutrition (CFSAN). Voluntary Cosmetic Registration Program - Frequency of Use of Cosmetic Ingredients. College Park, MD 2019 2019. (Obtained under the Freedom of Information Act from CFSAN; requested as "Frequency of Use Data" January 3, 2019; received February 13, 2019.)
28. Personal Care Products Council. 2018. Updated concentration of Use by FDA Product Category: Silicates. (Unpublished data submitted by Personal Care Products Council on June 11, 2018.)
29. Personal Care Products Council. 2018. Council Concentration of Use Survey: Silica Ingredients. (Unpublished data submitted by Personal Care Products Council on October 26, 2018.)

30. Rothe H, Fautz R, Gerber E, et al. Special aspects of cosmetic spray safety evaluations: Principles on inhalation risk assessment. *Toxicol Lett*. 2011;205(2):97-104.
31. Rothe H. Special Aspects of Cosmetic Spray Evaluation. Unpublished data presented at the 26 September CIR Expert Panel meeting. Washington, D.C.
32. Bremmer H, Prud'homme de Lodder L, Engelen J. Cosmetics Fact Sheet: To assess the risks for the consumer; Updated version for ConsExpo 4. Bilthoven, Netherlands 2006 2006. RIVM 320104001/2006. <http://www.rivm.nl/bibliotheek/rapporten/320104001.pdf>. Accessed 8/24/2011. Pages 1-77.
33. Johnsen M. The Influence of Particle Size. *Spray Technology and Marketing*. 2004;14(11):24-27.
34. CIR Science and Support Committee of the Personal Care Products Council (CIR SSC). 2015. Cosmetic Powder Exposure. (Unpublished data submitted by the Personal Care Products Council.)
35. Aylott R, Byrne G, Middleton J, Roberts M. Normal use levels of respirable cosmetic talc: Preliminary study. *Int J Cosmet Sci*. 1976;1(3):177-186.
36. Russell R, Merz R, Sherman W, Siverston J. The determination of respirable particles in talcum powder. *Food Cosmet Toxicol*. 1979;17(2):117-122.
37. Regulation (EC) No. 1223/2009 of the European Parliament and of the Council of 30 November 2009 on Cosmetic Products., (2009).
38. Australian Government Department of Health. National Industrial Chemicals Notification and Assessment Scheme (NICNAS). <https://www.nicnas.gov.au/chemical-information>. Last Updated: Accessed: 5/1/2018.
39. Jung S, Sielker S, Hanisch M, Libricht V, Schäfer E, Dammaschke T. Cytotoxic effects of four different root canal sealers on human osteoblasts. *PLoS ONE*. 2018;13(3):e0194467.
40. Ko H, Jeong Y, Kim M. Cytotoxicities and genotoxicities of cements based on calcium silicate and of dental formocresol. *Mutat Res*. 2017;815:28-34.
41. Raghavendra S, Jadhav G, Gathani K, Kotadia P. Bioceramics in endodontics - A review. *J Istanbul Univ Fac Dent*. 2017;51(3 Suppl 1):S128-S137.
42. Kaewamatawong T, Kawamura N, Okajima M, Sawada M, Morita T, Shimada A. Acute pulmonary toxicity caused by exposure to colloidal silica: Particle size dependent pathological changes in mice. *Toxicol Pathol*. 2005;33(7):743-749.
43. Javadzadeh Y, Jafari-Navimipour B, Nokhodchi A. Liquisolid technique for dissolution rate enhancement of a high dose water-insoluble drug (carbamazepine). *Int J Pharm*. 2007;341(1-2):26-34.
44. Villota R, Hawkes J. Food applications and the toxicological and nutritional implications of amorphous silicon dioxide. *Crit Rev Food Sci Nutr*. 1986;23(4):289-321.
45. Lewis R, Sr. *Hawley's Condensed Chemical Dictionary*. 15th ed. Hoboken, NJ: John Wiley & Sons, Inc.; 2007.

46. O'Neil M, (ed). *The Merck Index*. 15th ed: The Royal Society of Chemistry; 2013.
47. Sauer F, Laughland D, Davidson W. Silica metabolism in guinea pigs. *Can J Biochem Physiol*. 1959;37(2):183-191.
48. Sauer F, Laughland D, Davidson W. The silica content of guinea pig tissues as determined by chemical and isotopic techniques. *Can J Biochem Physiol*. 1959;37(10):1173-1181.
49. Paydar S, Noorafshan A, Dalfardi B, et al. Structural alteration in dermal vessels and collagen bundles following exposure of skin wound to zeolite-bentonite compound. *J Pharm*. 2016;2016:5843459.
50. Hazelton Laboratories. 1958. Progress Report No. 1; Acute oral administration, acute eye application. (Submitted by EPA in response to a FOI request in 2008. 66 pages.)
51. W.R. Grace & Co. 1981. Supplement to GRAS affirmation petition No. 1G0270: Silica gel for use as a carrier for flavors. (Submitted by the US FDA in response to a FOI request. 189 pages.)
52. Warheit D, McHugh T, Hartsky M. Differential pulmonary responses in rats inhaling crystalline, colloidal, or amorphous silica dusts. *Scand J Work Environ Health*. 1995;21(Suppl 2):19-21.
53. Newberne P, Wilson R. Renal damage associated with silicon compounds in dogs. *Proc Natl Acad Sci USA*. 1970;65(4):872-875.
54. Takizawa Y, Hirasawa F, Noritomi E, Aida M, Tsunoda H, Uesugi S. Oral ingestion of syloid to mice and rats and its chronic toxicity and carcinogenicity. *Acta Medica et Biologica*. 1988;36(1):27-56.
55. Low R, Absher P, Hemenway D, Giancola M. Bronchoalveolar lavage lipids in rats exposed to aerosolized silicon dioxide polymers. *Am Rev Resp Dis*. 1985;13:183.
56. Hemenway D, Abasher M, Landesman M, Trombley L, Emerson R. Differential lung response following silicon dioxide polymorph aerosol exposure. In: DF G, ed. *Silica, Silicosis and Cancer*. NY: Praeger Publ; 1986:105-116.
57. Warheit D, Carakostas M, Kelly D, Hardky M. Four-week inhalation toxicity study with Ludox colloidal silica in rats: Pulmonary cellular responses. *Fundam Appl Toxicol*. 1991;16(3):590-601.
58. Warheit D, Achinko L, Carakostas M, Hartsky M. Testing the efficacy of biomarkers to predict pulmonary toxicity of inhaled materials. *Am Rev Resp Dis*. 1990;141A:419.
59. Lee K, Kelly D. Translocation of particle-laden alveolar macrophages and intra-alveolar granuloma formation in rats exposed to Ludox colloidal amorphous silica by inhalation. *Toxicol*. 1993;77(3):205-222.
60. Reuzel P, Bruihintjes J, Reron V, Woutersen R. Subchronic inhalation toxicity of amorphous silicas and quartz dust in rats. *Fd Chem Toxic*. 1991;29(5):341-354.
61. Shin J, Jeon K, Kim J, et al. Subacute inhalation toxicity study of synthetic amorphous silica nanoparticles in Sprague-Dawley rats. *Inhal Toxicol*. 2017;29(12-14):567-576.

62. Johnston C, Driscoll K, Finkelstein J, et al. Pulmonary chemokine and mutagenic responses in rats after subchronic inhalation of amorphous and crystalline silica. *Toxicol Sci.* 2000;56(2):405-413.
63. Schepers G. Hypertension due to inhaled submicron amorphous silica. *Toxicol App Pharmacol.* 1959;1(5):487-500.
64. Schepers G, Durkan T, Delahant A, Creedon F, Redlin A. The biological action of Degussa submicron amorphous silica dust (Dow Corning Silica). I. Inhalation studies in rats. *AMA Arch Ind Health.* 1957;16(2):125-146.
65. Schepers G. Biological action of precipitation-process submicron amorphous silica (HI-SIL 233). In: DD D, ed. *Health Effects of Synthetic Silica Particulates, ASTM STP 732.* American Society for Testing and Materials; 1981:144-173.
66. Groth D, Moormann W, Lynch D, Stettler L, Wagner W, Hornung R. Chronic effects of inhaled amorphous silicas in animals. In: DD D, ed. *Health Effects of Synthetic Silica Particulates, ASTM STP 732.* American Society for Testing and Materials; 1981:118-143.
67. Schepers G, Durkan T, Delahant A, Creedon F, Redlin A. The biological action of inhaled Degussa submicron amorphous silica dust (Dow Corning Silica): II. The pulmonary reaction in uninfected guinea pigs. *AMA Arch Ind Health.* 1957;16(3):203-224.
68. Schepers G, Delahant A, Schmidt J, Von Wecheln J, Creedon F, Clark R. The biological action of Degussa submicron amorphous silica dust (Dow Corning Silica): III. Inhalation studies in rabbits. *AMA Arch Ind Health.* 1957;16(4):280-301.
69. Schepers G. Reaction of monkey lung to siliceous dust. *Arch Environ Health.* 1962;5(4):278-299.
70. Kanematsu N, Hara M, Kada T. Rec assay and mutagenicity studies on metal compounds. *Mutat Res.* 1980;77(2):109-116.
71. Prival M, Simmon V, Mortelmans K. Bacterial mutagenicity testing of 49 food ingredients gives very few positive results. *Mut Res.* 1991;260(4):321-329.
72. Liu X, Keane M, Zhong B-Z, Ong T, Wallace W. Micronucleus formation in V79 cells treated with respirable silica dispersed in medium and in simulated pulmonary surfactant. *Mutat Res.* 1996;361(2-3):89-94.
73. Zhong B, Ong T, Whong W. Studies on the relationship between treatment conditions and micronucleus induction in V79 cells exposed to silica and glass fiber. *Mutat Res.* 1997;391(1-2):111-116.
74. International Agency for Research on Cancer (IARC). 1997. Silica, Some Silicates, Coal Dust and *para*-Aramid Fibrils. Vol 68. Lyon, France: World Health Organization.
75. Campbell J. Effects of precipitated silica and of iron oxide on the incidence of primary lung tumours in mice. *Brit Med J.* 1940;2(4156):275-280.
76. Pott F, Roller M. Carcinogenicity study with nineteen granular dusts in rats. *Eur J Oncol.* 2005;10(4):249-281.

77. Epstein W, Skahen J, Krasnobrod H. The organized epithelioid cell granuloma: Differentiation of allergic (zirconium) from colloidal (silica) types. *Amer J Path.* 1963;43(3):391-405.
78. Anonymous. 1984. Safety data of hydrated silica - contact allergenicity (Translated into English in 2009). (Unpublished data submitted by the Personal Care Products Council.)
79. KGL Inc. 2003. An evaluation of the contact-sensitization potential of a topical coded product (facial mask containing 17% Hydrated Silica) in human skin by means of the maximization assay. KGL Protocol #5384. (Unpublished data submitted by the Personal Care Products Council.)
80. KGL Inc. 2004. An evaluation of the contact-sensitization potential of a topical coded product (face powder containing 21.7436% Silica) in human skin by means of the maximization assay. KGL Protocol #5632. (Unpublished data submitted by the Personal Care Products Council.)
81. Rathnamali B, Samarajiwa G, Abeyratne D, Perera G, Gunatilake S. Acute kidney injury following ingestion of plate developer (sodium metasilicate): A case report. *BMC Res Notes.* 2016;9(1):412.
82. Hannu T, Riihimäki V, Piirilä P. Reactive airways dysfunction syndrome from acute inhalation of dishwasher detergent powder. *Can Respir J.* 2012;19(3):e25-e28.
83. Plunkett E, DeWitt B. Occupational exposure to Hil-Sil and Silene: Report of an 18-year study. *Arch Environ Health.* 1962;5(5):469-472.
84. Wilson R, Stevens P, Lovejoy H, Bell Z, Richie R. Effects of chronic amorphous silica exposure on sequential pulmonary functions. *J Occup Med.* 1979;21(6):399-402.
85. Choudat D, Frisch C, Barrat G, El Kholti A, Conso F. Occupational exposure to amorphous silica dust and pulmonary function. *Br J Indust Med.* 1990;47(11):763-766.
86. U. S. Department of Labor. Silica, Amorphous, Precipitated and Gel. https://www.osha.gov/dts/chemicalsampling/data/CH_266700.html. Last Updated: 2018. Accessed: 6/1/2018.
87. Volk H. The health of workers in a plant making highly dispersed silica. *Arch Environ Health.* 1960;1(2):125-128.
88. National Institute for Occupational Safety and Health (NIOSH). NIOSH Pocket Guide to Chemical Hazards: Silica, amorphous. <https://www.cdc.gov/niosh/npg/npgd0552.html>. Last Updated: 2018. Accessed: 11/1/2018.